Your basket is currently empty!
Catalog Pro5® MHC Class I Pentamers
Catalog Pro5® MHC Class I Pentamers
Pentamer Research Areas – Select a disease area to view publications demonstrating the use of Pentamers
| AAV | Adenovirus | Autoimmunity | BK Virus |
| Cancer | Chlamydia | CMV | COVID-19 / SARS-CoV-2 |
| Dengue | EBV | HAV | HBV |
| HCV | HIV/SIV | HPV | HSV |
| HTLV | Influenza | JC Virus | LCMV |
| Listeria | Malaria | MiHAg | Model Antigens |
| MuLV | Negative | Norovirus | Other |
| Rabies | RSV | Sendai Virus | SV40 Virus |
| Toxoplasma gondii | Trypanosoma | Tuberculosis | Vaccinia |
| Varicella Zoster Virus | VSV | West Nile Virus | Yellow Fever Virus |
Search the table below by disease, allele, specificity or sequence, or any combination, e.g. “CMV A*02:01 pp65”. If your specificity is not listed, we can synthesize Custom MHC Class I Pentamers at no additional cost.
| DISEASE | ALLELE | PEPTIDE CODE | PEPTIDE SEQUENCE | EPITOPE ORIGIN |
|---|---|---|---|---|
| AAV | A*01:01 | 886 | SADNNNSEY | AAV VP1 492-500 |
| AAV | B*07:02 | 651 | VPQYGYLTL | AAV2 372-380 |
| AAV | H-2Kd | KYLGPFNGL | capsid protein 51-59 | |
| Adenovirus | A*01:01 | 686 | TDLGQNLLY | Adenovirus 5 Hexon 886-894 |
| Adenovirus | A*02:01 | YVLFEVFDVV | Hexon major capsid protein 916–925 | |
| Adenovirus | A*24:02 | 684 | TYFSLNNKF | Adenovirus 5 Hexon 37-45 |
| Adenovirus | B*07:02 | 685 | KPYSGTAYNSL | AdV Hexon |
| Adenovirus | B*07:02 | 989 | KPYSGTAYNAL | Adenovirus Hexon 114-124 |
| Adenovirus | B*35:01 | 1346 | IPYLDGTFY | AdV Hexon |
| Adenovirus | H-2Db | 2206 | SGPSNTPPEI | Ad5 E1A 234-243 |
| Adenovirus | H-2Db | VNIRNCCYI | E1B protein 192-200 | |
| AutoImmunity | A*02:01 | 151 | KLQVFLIVL | T1D Diabetes human prepro islet amyloid polypeptide ppIAPP 5-13 |
| AutoImmunity | A*02:01 | 393 | VMNILLQYV | GAD65 114-123 |
| AutoImmunity | A*02:01 | 470 | SLSRFSWGA | Myelin basic protein 110-118 |
| AutoImmunity | A*02:01 | 851 | HLVEALYLV | Insulin B chain 10-18 |
| AutoImmunity | A*02:01 | 954 | LNIDLLWSV | T1D Diabetes IGRP 228-236 |
| Autoimmunity | A*02:01 | 1904 | VLFGLGFAI | T1D Diabetes IGRP 265-273 |
| Autoimmunity | A*02:01 | 2259 | ALWGPDPAAA | Proinsulin precursor 15-24 |
| Autoimmunity | A*02:01 | 2382 | MVWESGCTV | IA-2 797-805 |
| Autoimmunity | A*02:01 | 3342 | YTCPLCRAPV | SSA SS-56 55-64 |
| Autoimmunity | A*02:01 | 3394 | VIVMLTPLV | IA-2 805-813 |
| Autoimmunity | A*02:01 | 969 | RLLPLLALL | Insulin Precursor 76-90 |
| Autoimmunity | A*02:01 | LLNATIAEV | steroid 21-hydroxylase (21OH) 342-350 | |
| Autoimmunity | A*02:01 | LLIGGFAGL | thyroperoxidase (TPO) 857-865 | |
| Autoimmunity | A*02:01 | ALARWLPPV | Thyroid peroxidase 172-180 | |
| Autoimmunity | A*02:01 | HIAGSLAVV | Zinc transporter 8 (ZnT-8) 93-101 | |
| Autoimmunity | A*02:01 | FLALSILVL | Calcitonin 9-17 | |
| Autoimmunity | A*02:01 | ILLAELEQL | Vimentin 130-138 | |
| Autoimmunity | A*02:01 | LLAGIGTVPI | prostaglandin transporter (hPGT) / solute carrier protein (SLCO2A1) 178-187 | |
| Autoimmunity | A*02:01 | SLDALITHV | Alcohol dehydrogenase 1B (ADH1B) 342-350 | |
| Autoimmunity | A*02:01 | GIIYIIYKL | Genome polyprotein 1505-1513 | |
| Autoimmunity | A*02:01 | KLKDVLLQV | Myosin-9 1843-1851 | |
| Autoimmunity | A*02:01 | FLLSLFSLWL | Zinc transporter 8 (ZnT-8) 114-123 | |
| Autoimmunity | A*02:01 | RLLDLAQEGL | Cytochrome P450 2D6 (CYP2D6) 204-213 | |
| Autoimmunity | A*02:01 | GLEALVPLAV | Cytochrome P450 2D6 (CYP2D6) 204-213 | |
| Autoimmunity | A*02:01 | ILKDFSILL | Zinc transporter 8 (ZnT-8) 266-274 | |
| Autoimmunity | A*02:01 | ALYDATYET | Cofilin-1 (CFL1) 83-91 | |
| Autoimmunity | A*02:01 | KLANPLPYT | spermine oxidase (SMOX) | |
| Autoimmunity | A*02:01 | GMVTTSTTL | Cytochrome P450 2D6 (CYP2D6) 304-314 | |
| Autoimmunity | A*02:01 | KLSEGDLLA | pyruvate dehydrogenase complex subunit E2 (PDC-E2) 159-167 | |
| Autoimmunity | A*03:01 | MVPFIPLYR | Tyrosinase 426–434 | |
| Autoimmunity | A*03:01 | ALYLVCGER | Insulin (38-46) | |
| Autoimmunity | A*29:02 | VTLTCAFRY | Retinal S-antigen (SAG / Arrestin) 63-71 | |
| Autoimmunity | B*07:02 | RPPGGSGPLL | F-box only protein 7 (FBXO7) 3-12 | |
| Autoimmunity | B*07:02 | APREPFAHSL | Zinc finger CCCH-type-containing protein 12D (ZC3H12D) 321-330 | |
| Autoimmunity | B*08:01 | EPLARLEL | 21-hydroxylase (CYP21A2) 431-438 | |
| Autoimmunity | B*27:05 | RRYQKSTEL | Histone H3.3 53-61 | |
| Autoimmunity | B*27:05 | HRVYLVRKL | Human E3 ubiquitin-protein ligase RNF213 4275 to 4283 | |
| Autoimmunity | B*27:05 | SRVLQNVAF | bcl-2-related protein A1 isoform 1 34-42 | |
| Autoimmunity | H-2Db | 1107 | RSPFSRVVHL | MOG Precursor 69-78 |
| Autoimmunity | H-2Db | RMLENYEEI | Cullin-7 373-381 | |
| Autoimmunity | H-2Db | HAFENLEII | Epidermal growth factor receptor isoform 1 precursor 418-426 | |
| Autoimmunity | H-2Db | LSIQNYHVFL | Apolipoprotein B-100 4463-4472 | |
| Autoimmunity | H-2Db | YAASNGVLM | Ornithine Decarboxylase (ODC) | |
| Autoimmunity | H-2Db | NGVINAAFM | Phosphatidylinositol-binding clathrin assembly protein (AP180) 190-198 | |
| Autoimmunity | H-2Db | ISGVNRYYV | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 1 (NDUFA1) 54-62 | |
| Autoimmunity | H-2Db | SAVRLRSSV | Vimentin 66-74 | |
| Autoimmunity | H-2Kb | SNYLFTKL | endothelial PAS domain-containing protein 1 386-393 | |
| Autoimmunity | H-2Kb | RTYTYEKL | catenin beta-1 329-336 | |
| Autoimmunity | H-2Kb | VPYAFKSL | Apolipoprotein B-100 4281-4288 | |
| Autoimmunity | H-2Kb | SSYTFPKM | Enoyl-CoA delta isomerase 2 (EICI2) 280-287 | |
| Autoimmunity | H-2Kb | VGPRYTNL | mitogen-activated protein kinase 1 (Mapk1) 19-26 | |
| Autoimmunity | H-2Kb | INFDFPKL | Probable ATP-dependent RNA helicase DDX6 (p54 Rna Helicase) 407-414 | |
| Autoimmunity | H-2Kb | RAYLFNSV | yippee-like 1 (YPEL1) 47–54 | |
| Autoimmunity | H-2Kb | KIITYRNL | PCI domain-containing protein 2 318-325 | |
| Autoimmunity | H-2Kb | VNQVYSTL | Apolipoprotein B-100 2533-2540 | |
| Autoimmunity | H-2Kb | TNLKYSPL | Apolipoprotein B-100 1658-1665 | |
| Autoimmunity | H-2Kb | VSFTYRYL | vacuolar protein sorting 16 (VPS16) 227-234 | |
| Autoimmunity | H-2Kb | KILTFDQL | 60S ribosomal protein L18 (RPL18) 119-126 | |
| Autoimmunity | H-2Kb | VINPYKNL | Myosin-9 (MYH9) 120-127 | |
| Autoimmunity | H-2Kb | VAFDFTKV | Phosphatidylinositol-binding clathrin assembly protein (PICALM) 141-148 | |
| Autoimmunity | H-2Kb | VIVRFLTV | 40S ribosomal protein S15a (RPS15A) 33-40 | |
| Autoimmunity | H-2Kb | HILIYSDV | myosin binding protein C 399-406 | |
| Autoimmunity | H-2Kd | GYFEVTHDI | Catalase 83-91 | |
| Autoimmunity | H-2Kd | HFLPMLQTV | Myosin light polypeptide 6 (MYL6) 69-77 | |
| Autoimmunity | H-2Kd | 580 | VYLKTNVFL | IGRP (206-214) |
| BK virus | A*02:01 | 1516 | AITEVECFL | VP1 44-52 |
| BK virus | A*02:01 | 1783 | FLHCIVFNV | large T antigen 410-418 |
| BK virus | A*02:01 | 3781 | LLMWEAVTV | VP1 108-116 |
| BK virus | A*02:01 | 3903 | CLLPKMDSV | large T antigen 398-406 |
| BK Virus | A*11:01 | AVDTVLAKK | Large T antigen 342-350 | |
| BK virus | B*07:02 | 2070 | LPLMRKAYL | LT antigen 27-35 |
| BK Virus | B*07:02 | APKKPKEPV | Viral capsid protein 1 (VP1) 14-22 | |
| BK Virus | B*07:02 | GPLCKADSL | Major capsid protein VP1 252-160 | |
| BK Virus | B*07:02 | NPTAQSQVM | VP1 182-190 | |
| BK Virus | B*35:01 | EPLVWIDCY | small t 129-137 | |
| Cancer | A*01:01 | 29 | EADPTGHSY | MAGE-A1 161-169 |
| Cancer | A*01:01 | 30 | EVDPIGHLY | MAGE-A3 168-176 |
| Cancer | A*01:01 | 307 | KSDICTDEY | Tyrosinase 243-251 (244S) |
| Cancer | A*01:01 | 467 | KCDICTDEY | Tyrosinase 243-251 |
| Cancer | A*01:01 | 1542 | QSLEIISRY | Mcl-1 177-185 |
| Cancer | A*01:01 | 2102 | YVDFREYEYY | FLT3 ITD |
| Cancer | A*01:01 | 3383 | TLDTLTAFY | Mesothelin 429-437 |
| Cancer | A*01:01 | 3622 | LTDDRLFTCY | PLEKHM2 |
| Cancer | A*01:01 | 3623 | DSDPDSFQDY | Tyr A1a 454-463 |
| Cancer | A*01:01 | 3624 | EADPIGHLY | MAGEA3 |
| Cancer | A*01:01 | 3626 | EVDPASNTY | MAGE-A4 169-177 |
| Cancer | A*01:01 | 3627 | HSTNGVTRIY | PSMA |
| Cancer | A*01:01 | 3628 | ILDTAGREEY | N-ras 55-64 |
| Cancer | A*01:01 | 3630 | LVDVMPWLQY | Cytochrome P450 240-249 |
| Cancer | A*01:01 | 3632 | RSDSGQQARY | AIM-2 |
| Cancer | A*01:01 | 3633 | VTEPGTAQY | Minor antigen HA-3T (Lbc oncogene 451-459) |
| Cancer | A*01:01 | 3634 | VYDFFVWLHY | TRP-2 181-190 |
| Cancer | A*01:01 | YTDSSSILNY | UHRF1-binding protein 1-like 1004–1013 | |
| Cancer | A*01:01 | YSDKYGLGY | Polo-like kinase 1 (PLK1) 417-425 | |
| Cancer | A*01:01 | ESDPIVAQY | Titin 23410-23418 | |
| Cancer | A*01:01 | SSDYVIPIGTY | Tyrosinase 146-156 | |
| Cancer | A*01:01 | DSDSEEPSKY | Receptor-type tyrosine-protein phosphatase C (PTPRC) 1008-1017 | |
| Cancer | A*01:01 | ILDTAGLEEY | KRAS Q61L 55-64 | |
| Cancer | A*01:01 | ILDTAGKEEY | Neuroblastoma RAS viral oncogene homolog (NRAS) Q61K 55-64 | |
| Cancer | A*01:01 | NSEEHSARY | highly similar to PX domain-containing protein kinase-like protein 441-449 | |
| Cancer | A*01:01 | ILDTAGQEEY | KRAS 55-64 | |
| Cancer | A*01:01 | NLDKNLIKY | Receptor-type tyrosine-protein phosphatase C 434-442 | |
| Cancer | A*01:01 | YVDILPYDY | Receptor-type tyrosine-protein phosphatase C 683-691 | |
| cancer | A*01:01 | LSHIHASSY | Preferentially expressed antigen in melanoma 267-275 | |
| Cancer | A*02:01 | 34 | FLWGPRALV | MAGEA3 271-279 |
| Cancer | A*02:01 | 46 | IMDQVPFSV | gp100 (pmel17) 209-217 |
| Cancer | A*02:01 | 47 | YLEPGPVTV | gp100 (pmel) 280-288 (288V) |
| Cancer | A*02:01 | 48 | YLSGADLNL | Carcinoembryonic antigen (CEA)-derived peptide CAP1-6D |
| Cancer | A*02:01 | 49 | SLLMWITQC | NY-ESO-1 157-165 (9C) |
| Cancer | A*02:01 | 57 | KTWGQYWQV | gp100 (pmel17) 154-162 |
| Cancer | A*02:01 | 58 | YLEPGPVTA | gp100 |
| Cancer | A*02:01 | 61 | YMDGTMSQV | Tyrosinase 369-377 (371D) |
| Cancer | A*02:01 | 75 | YLSGANLNL | Carcinogenic Embryonic Antigen (CEA) 571-579 |
| Cancer | A*02:01 | 82 | ELAGIGILTV | MelanA / MART 26-35 |
| Cancer | A*02:01 | 85 | ILAKFLHWL | Telomerase 540-548 |
| Cancer | A*02:01 | 86 | ALQPGTALL | Prostate Stem Cell Antigen (PSCA) 14-22 |
| Cancer | A*02:01 | 97 | VISNDVCAQV | Prostate Specific Antigen-1 (PSA-1) 154-163 |
| Cancer | A*02:01 | 117 | RLVDDFLLV | Telomerase Reverse Transcriptase 865-873 |
| Cancer | A*02:01 | 125 | GVLVGVALI | Carcinogenic Embryonic Antigen (CEA) 694-702 |
| Cancer | A*02:01 | 157 | VLYRYGSFSV | gp100 (pmel17) 476-485 |
| Cancer | A*02:01 | 162 | PLFQVPEPV | Alpha-fetoprotein isoform 1 137-145 |
| Cancer | A*02:01 | 163 | FMNKFIYEI | Human alfa fetoprotein 158-166 |
| Cancer | A*02:01 | 164 | GLSPNLNRFL | Alpha-fetoprotein isoform 2 167-176 |
| Cancer | A*02:01 | 171 | KVLEYVIKV | MAGEA1 278-286 |
| Cancer | A*02:01 | 205 | LLGRNSFEV | p53 264-272 |
| Cancer | A*02:01 | 208 | LLLLTVLTV | MUC-1 12-20 |
| Cancer | A*02:01 | 210 | ILHNGAYSL | HER-2/neu 435-443 |
| Cancer | A*02:01 | 212 | RLLQETELV | HER-2/neu 689-697 |
| Cancer | A*02:01 | 214 | KIFGSLAFL | HER-2/neu 369-377 |
| Cancer | A*02:01 | 220 | LLLLDVAPL | HSP1A 459-467 |
| Cancer | A*02:01 | 221 | LLDVAPLSL | HSP1A 461-469 |
| Cancer | A*02:01 | 226 | HLYQGCQVV | Receptor tyrosine-protein kinase erbB-2 48-56 |
| Cancer | A*02:01 | 249 | HLSTAFARV | G250 (renal cell carcinoma) 217-225 |
| Cancer | A*02:01 | 250 | VLQELNVTV | Leukocyte Proteinase-3 (Wegener's autoantigen) 169-177 |
| Cancer | A*02:01 | 302 | KVAELVHFL | MAGEA3 112-120 |
| Cancer | A*02:01 | 304 | VLAGVGFFI | EPHA2 550-558 |
| Cancer | A*02:01 | 306 | FLYTLLREV | STEAP 86-94 |
| Cancer | A*02:01 | 329 | ILLWQPIPV | Prostatic Acid Phosphatase-3 (PAP-3) 135-143 |
| Cancer | A*02:01 | 337 | RLQEERTCKV | BIR |
| Cancer | A*02:01 | 338 | QLCPICRAPV | Livin/ML-IAP280 175-184 |
| Cancer | A*02:01 | 345 | VLGEAWRDQV | TRAP 45-54 |
| Cancer | A*02:01 | 381 | LLLTVLTVV | Tumor Mucin Antigen 13-21 |
| Cancer | A*02:01 | 389 | GLYDGMEHL | MAGEA-10 254-262 |
| Cancer | A*02:01 | 390 | SLLMWITQV | NY-ESO-1 157-165 |
| Cancer | A*02:01 | 391 | LMLGEFLKL | Survivin 96-104 |
| Cancer | A*02:01 | 394 | YLFFYRKSV | mTERT 572-580 |
| Cancer | A*02:01 | 404 | FLTPKKLQCV | Prostate Specific Antigen-1 (PSA-1) 141-150 |
| Cancer | A*02:01 | 405 | KLQCVDLHV | Prostate Specific Antigen 146-154 |
| Cancer | A*02:01 | 408 | TLAPATEPA | Mucin 79-87 |
| Cancer | A*02:01 | 447 | YLQVNSLQTV | Telomerase Reverse Transcriptase (hTRT) 988-997 |
| Cancer | A*02:01 | 452 | SLGEQQYSV | WT1 187-195 |
| Cancer | A*02:01 | 457 | SLEENIVIL | RHAMM 275-283 |
| Cancer | A*02:01 | 464 | YMNGTMSQV | Tyrosinase 368-376 |
| Cancer | A*02:01 | 468 | ILSLELMKL | Receptor for hyaluronic acid-mediated motility (RHAMM) 165-173 |
| Cancer | A*02:01 | 480 | PLFDFSWLSL | Bcl-2 208-217 |
| Cancer | A*02:01 | 516 | LLGATCMFV | CyclinD 101-109 |
| Cancer | A*02:01 | 527 | ALYVDSLFFL | PRAME PRA 300-309 |
| Cancer | A*02:01 | 560 | GLMEEMSAL | Human Mena protein (overexpressed in breast cancer) |
| Cancer | A*02:01 | 561 | TMNGSKSPV | hMena 502-510 |
| Cancer | A*02:01 | 575 | GVYDGREHTV | MAGE-A4 230-239 |
| Cancer | A*02:01 | 594 | YLNDHLEPWI | Bcl-X 173-182 |
| Cancer | A*02:01 | 599 | ALDVYNGLL | Prostatic acid phosphatase precursor (PAP) 299-307 |
| Cancer | A*02:01 | 600 | ALFDIESKV | PSM P2 (prostate) |
| Cancer | A*02:01 | 637 | SLAMLDLLHV | Mutant anaplastic lymphoma kinase 1220-1229 |
| Cancer | A*02:01 | 645 | YLNTVQPTCV | EGF-R 1138-1147 |
| Cancer | A*02:01 | 646 | KLFGTSGQKT | EGF-R-479 350-359 |
| Cancer | A*02:01 | 654 | RMPEAAPPV | p53 65-73 |
| Cancer | A*02:01 | 655 | KLVVVGADGV | KRAS G12D (5-14) |
| Cancer | A*02:01 | 752 | KLVVVGAVGV | KRAS G12V (5-14) |
| Cancer | A*02:01 | 662 | PLTSIISAV | Receptor tyrosine-protein kinase erbB-2 728-736 |
| Cancer | A*02:01 | 689 | VLAGGFFLL | PSMA 27-38 |
| Cancer | A*02:01 | 690 | LLHETDSAV | PSMA/PSM-P1 4-12 |
| Cancer | A*02:01 | 693 | VMAGVGSPYV | Receptor tyrosine-protein kinase erbB-2 819-828 |
| Cancer | A*02:01 | 773 | VLPLTVAEV | Mesothelin 530-538 |
| Cancer | A*02:01 | 774 | SLLFLLFSL | Mesothelin 20-28 |
| Cancer | A*02:01 | 780 | QLFEELQEL | Heme oxygenase-1 212-220 |
| Cancer | A*02:01 | 781 | VLDGLDVLL | PRAME 100-108 |
| Cancer | A*02:01 | 787 | RLASFYDWPL | BIR7 90-99 |
| Cancer | A*02:01 | 810 | LIAHNQVRQV | HER-2/neu (85-94) |
| Cancer | A*02:01 | 811 | ILHDGAYSL | HER-2 434-443 |
| Cancer | A*02:01 | 813 | FVGEFFTDV | GPC3 144-152 (overexpressed in hepatocellular carcinoma) |
| Cancer | A*02:01 | 841 | LLLIWFRPV | BKV Ltag 579-587 |
| Cancer | A*02:01 | 859 | KLQDASAEV | HM1.24-aa 126-134 |
| Cancer | A*02:01 | 861 | SLLQHLIGL | PRAME 425-433 |
| Cancer | A*02:01 | 862 | VIFDFLHCI | BKV Ltag 406-414 |
| Cancer | A*02:01 | 893 | VLDFAPPGA | WT1 |
| Cancer | A*02:01 | 915 | TLPGYPPHV | PAX-5 311-319 |
| Cancer | A*02:01 | 921 | YMEHNNVYTV | Fibromodulin 250-259 |
| Cancer | A*02:01 | 922 | YLQHNEIQEV | Fibromodulin 206-215 |
| Cancer | A*02:01 | 958 | SLVDVMPWL | Cytochrome p450 1B1 239-248 |
| Cancer | A*02:01 | 960 | RLMNDMTAV | HSP105 128-136 |
| Cancer | A*02:01 | 997 | RLARLALVL | Trophoblast glycoprotein 17-25 |
| Cancer | A*02:01 | 998 | FLTGNQLAV | 5T4 97-105 |
| Cancer | A*02:01 | 1007 | LLLAGLFSL | Fibromodulin 7-15 |
| Cancer | A*02:01 | 1013 | FLGYLILGV | Prostatic Acid Phosphatase-3 (PAP-3) |
| Cancer | A*02:01 | 1056 | SLFLGILSV | CD20 188-196 (B cell malignancies) |
| Cancer | A*02:01 | 1130 | AVLPLLELV | MCL-1 139-147 |
| Cancer | A*02:01 | 1181 | SLSEKTVLL | CD59 glycoprotein precursor 106-114 |
| Cancer | A*02:01 | 1201 | YMCSFLFNL | Ewing Tumor EZH2 666-674 |
| Cancer | A*02:01 | 1239 | YLISGDSPV | CD33 65-73 (1Y2L) |
| Cancer | A*02:01 | 1246 | KASEKIFYV | SSX2 41-49 |
| Cancer | A*02:01 | 1302 | FLAKLNNTV | HCA587 317-325 |
| Cancer | A*02:01 | 1386 | GLAPPQHLIRV | p53 187-197 |
| Cancer | A*02:01 | 1403 | VIMPCSWWV | Chondromodulin-I 319-327 |
| Cancer | A*02:01 | 1421 | KVVEFLAML | MAGE-C1 1083-1091 |
| Cancer | A*02:01 | 1464 | LTLGEFLKL | Survivin-3A 96-104 |
| Cancer | A*02:01 | 1508 | ALPFGFILV | IL13R 345-353 |
| Cancer | A*02:01 | 1509 | TLADFDPRV | EphA2 |
| Cancer | A*02:01 | 1778 | ALMEQQHYV | ITGB8 662-670 |
| Cancer | A*02:01 | 1779 | CLTSTVQLV | HER-2/neu 789-797 |
| Cancer | A*02:01 | 1786 | GLLGASVLGL | Telomerase Reverse Transcriptase (hTRT) 674-683 |
| Cancer | A*02:01 | 1908 | QLLDGFMITL | PASD1 39-48 |
| Cancer | A*02:01 | 1910 | YLVGNVCIL | PASD1 168-176 |
| Cancer | A*02:01 | 1920 | ALLTSRLRFI | Telomerase Reverse Transcriptase (hTRT) 615-624 |
| Cancer | A*02:01 | 1937 | RLSSCVPVA | 131-139 |
| Cancer | A*02:01 | 2079 | FLYDDNQRV | Topoisomerase II-alpha-b 828-836 |
| Cancer | A*02:01 | 2081 | YLIELIDRV | TACE 250-258 |
| Cancer | A*02:01 | 2083 | FLAEDALNTV | Epithelial Discoidin Domain Receptor 1 (EDDR1) 867-876 |
| Cancer | A*02:01 | 2236 | GLMKYIGEV | TRPM8 187-195 |
| Cancer | A*02:01 | 2291 | AILALLPAL | Prostate Stem Cell Antigen (PSCA) 105-133 |
| Cancer | A*02:01 | 2293 | GLQHWVPEL | BA46 (Lactadherin) 97-106 |
| Cancer | A*02:01 | 2294 | GVRGRVEEI | BCR-ABL |
| Cancer | A*02:01 | 2296 | ITDQVPFSV | gp100 (pmel) 209-217 |
| Cancer | A*02:01 | 2297 | KLCPVQLWV | p53 139-147 |
| Cancer | A*02:01 | 2298 | KVAEELVHFL | MAGEA3 112-120 (alternative version) |
| Cancer | A*02:01 | 2299 | SLPPPGTRV | p53 149-157 |
| Cancer | A*02:01 | 2300 | YLGSYGFRL | p53 103-111 |
| Cancer | A*02:01 | 2301 | YLQLVFGIEV | MAGEA2 157-166 |
| Cancer | A*02:01 | 2371 | TLQDIVYKL | BMI1 74-82 |
| Cancer | A*02:01 | 2457 | YAIDLPVSV | L-dopachrome tautomerase 488-496 |
| Cancer | A*02:01 | 2569 | AMVGAVLTA | Tyrosinase 482-190 |
| Cancer | A*02:01 | 2582 | ATVGIMIGV | CEACAM5 687-695 |
| Cancer | A*02:01 | 2649 | YVDPVITSI | Hepatocyte growth factor receptor 673-681 |
| Cancer | A*02:01 | 2669 | GVLLWEIFSL | VEGFR1 28-37 |
| Cancer | A*02:01 | 2778 | GLSNLTHVL | PRAME (432-440) |
| Cancer | A*02:01 | 2793 | LMAQEALAFL | CAMEL 2-11 |
| Cancer | A*02:01 | 2860 | ALLPAVPSL | Wilms Tumor Protein 83-91 |
| Cancer | A*02:01 | 2988 | RVA(PHOSPHO-S)PTSGV | Insulin receptor substrate-2 1097-1105 |
| Cancer | A*02:01 | 2990 | RVASPTSGV | IRS-2 1097-1105 |
| Cancer | A*02:01 | 3006 | KVDELAHFL | Melanoma-associated antigen 4 (MAGE4) 113-121 |
| Cancer | A*02:01 | 3080 | KVLEHVVRV | Melanoma-associated antigen 4 (MAGE4) 286-294 |
| Cancer | A*02:01 | 3343 | ALNVYNGLL | ACPP 299-307 |
| Cancer | A*02:01 | 3344 | ALSPVPPVV | Bcl-2 85-93 |
| Cancer | A*02:01 | 3345 | ALVCYGPGI | FAP alpha 463-471 |
| Cancer | A*02:01 | 3346 | ALWPWLLMAT | RNF43 11-20 |
| Cancer | A*02:01 | 3347 | ALYLMELTM | CB9L2 |
| Cancer | A*02:01 | 3350 | CLPSPSTPV | BMI1 271-279 |
| Cancer | A*02:01 | 3352 | ELSDSLGPV | PASD1 695-703 |
| Cancer | A*02:01 | 3355 | FLFLRNFSL | TARP(V28L)27-35 |
| Cancer | A*02:01 | 3356 | FLPSPLFFFL | TARP(P5L) 5-13 |
| Cancer | A*02:01 | 3357 | GLFKCGIAV | FAP 639-647 |
| Cancer | A*02:01 | 3358 | GLIQLVEGV | TRAG-3 4-12 |
| Cancer | A*02:01 | 3361 | ILGVLTSLV | DLK1 309-317 |
| Cancer | A*02:01 | 3363 | LLVPTCVFLV | 691-700 |
| Cancer | A*02:01 | 3365 | MLAVFLPIV | STEAP 292-300 (293L) |
| Cancer | A*02:01 | 3366 | NLFETPVEA | 194-202 |
| Cancer | A*02:01 | 3368 | QLGEQCWTV | PSCA 44-51 (51A) |
| Cancer | A*02:01 | 3371 | RLAEYQAYI | SART3 309-317 |
| Cancer | A*02:01 | 3374 | SIDWFMVTV | p31-39 |
| Cancer | A*02:01 | 3375 | SILLRDAGLV | TRAG-3 57-66 |
| Cancer | A*02:01 | 3377 | SLFEPPPPG | PSMA 85-93 |
| Cancer | A*02:01 | 3379 | SQADALKYV | EZH2 729-737 |
| Cancer | A*02:01 | 3386 | WLSLKTLLSL | Bcl-2 214-223 |
| Cancer | A*02:01 | 3387 | YLNRHLHTWI | BCL-2 180-189 |
| Cancer | A*02:01 | 3388 | YLQWIEFSI | Prominin1 744-752 |
| Cancer | A*02:01 | 3389 | YLYQWLGAPV | Osteocalcin 51-60 |
| Cancer | A*02:01 | 3416 | KLMSSNSTDL | HSP105 234-243 |
| Cancer | A*02:01 | 3417 | SLYSYFQKV | Membrane-associated transporter protein |
| Cancer | A*02:01 | 3436 | RLQGISPKI | SSX2 103-111 |
| Cancer | A*02:01 | 3636 | AILALLPALL | PSCA |
| Cancer | A*02:01 | 3638 | ALIHHNTHL | HER2 466-474 |
| Cancer | A*02:01 | 3641 | CMHLLLEAV | MG50 624-632 |
| Cancer | A*02:01 | 3643 | FLIIWQNTM | FSP26 |
| Cancer | A*02:01 | 3644 | FLPWHRLFLL | Tyrosinase 207-216 |
| Cancer | A*02:01 | 3647 | FVWLHYYSV | TRP2 185-193(L) |
| Cancer | A*02:01 | 3648 | GLFGDIYLA | CSNK1A1 26-34 |
| Cancer | A*02:01 | 3649 | GLFGDIYLAI | CSNK1A1 26-35 |
| Cancer | A*02:01 | 3654 | ILLRDAGLV | TRAG-3L 58-66 |
| Cancer | A*02:01 | 3655 | ILLVVVLGV | Receptor tyrosine-protein kinase erbB-2 707-715 |
| Cancer | A*02:01 | 3656 | ILNAMIAKI | HAUS3 154-162 |
| Cancer | A*02:01 | 3658 | KASEYLQLV | MAGEA2 153-161 |
| Cancer | A*02:01 | 3659 | KIWEELSVL | MAGEA3 220-228 |
| Cancer | A*02:01 | 3660 | KLIDRTE(S)L | LSP1 325-333 |
| Cancer | A*02:01 | 3661 | KLTGDENFTI | Tyrosinase precursor 224-233 |
| Cancer | A*02:01 | 3662 | LLCYSCKAQV | PSCA 17-26 |
| Cancer | A*02:01 | 3666 | LLLEAVPAV | MG50 69-77 |
| Cancer | A*02:01 | 3668 | LLNQLQVNL | Mucin2 467-475 |
| Cancer | A*02:01 | 3669 | LLRDAGLVKM | TRAP 59-68 |
| Cancer | A*02:01 | 3670 | LLRRYNVAKV | SOX11 266-275 |
| Cancer | A*02:01 | 3671 | LLSHGAVIEV | Ankyrin NYBR1 158-167 |
| Cancer | A*02:01 | 3673 | LVFGIELMEV | MAGEA3 160-169 |
| Cancer | A*02:01 | 3674 | LVFGIEVVEV | MAGEA12 160-169 |
| Cancer | A*02:01 | 3675 | MLWGWREHV | Mucin2 645-653 |
| Cancer | A*02:01 | 3678 | PLQPEQLQV | Receptor tyrosine-protein kinase erbB-2 437-445 |
| Cancer | A*02:01 | 3680 | QLMAFNHLI | PAX3/FKHR 135-143 |
| Cancer | A*02:01 | 3681 | QLMPYGCLL | Receptor tyrosine-protein kinase erbB-2 845-853 |
| Cancer | A*02:01 | 3684 | RLGPTLMCL | MG50 1244-1252 |
| Cancer | A*02:01 | 3687 | RLTRFLSRV | CyclinD 228-236 |
| Cancer | A*02:01 | 3688 | RTF(S)PTYGL | Desmuslin 426-434 |
| Cancer | A*02:01 | 3689 | SILLRDAGL | TRAP 57-65 |
| Cancer | A*02:01 | 3691 | SLADEAEVYL | GAS7 Neoepitope |
| Cancer | A*02:01 | 3693 | SLDDYNHLV | L-dopachrome tautomerase 288-296 |
| Cancer | A*02:01 | 3695 | SLYKFSPFPL | O-linked N-acetylglucosamine transferase FSP06 |
| Cancer | A*02:01 | 3696 | SMTR(S)PPRV | SFRS2B 241-249 |
| Cancer | A*02:01 | 3698 | TLEEITGYL | Receptor tyrosine-protein kinase erbB-2 448-456 |
| Cancer | A*02:01 | 3699 | TLHCDCEIL | MG50 210-218 |
| Cancer | A*02:01 | 3702 | VLEPPGARDV | BIR 7 230-239 |
| Cancer | A*02:01 | 3704 | VLLALLMAGL | Prostate stem cell antigen 4-13 |
| Cancer | A*02:01 | 3705 | VLSVNVPDV | MG50 625-633 |
| Cancer | A*02:01 | 3706 | VLVKSPNHV | Receptor tyrosine-protein kinase erbB-4 890-898 |
| Cancer | A*02:01 | 3708 | VMIG(S)PKKV | Tensin3 1558-1566 |
| Cancer | A*02:01 | 3709 | VVLGVVFGI | Receptor tyrosine-protein kinase erbB-2 743-751 |
| Cancer | A*02:01 | 3710 | WLPKILGEV | MG50 1051-1059 |
| Cancer | A*02:01 | 3711 | WLQYFPNPV | Cytochrome P450 246-254 |
| Cancer | A*02:01 | 3713 | YLLDLSTNHL | Fibromodulin 7-15 |
| Cancer | A*02:01 | 3715 | YLWWVNNQSL | CEA 176-185 |
| Cancer | A*02:01 | 3718 | ALGGHPLLGV | Dickkopf-related protein 1 20-29 |
| Cancer | A*02:01 | 3719 | ALLAGLVSL | FGFR4 676-684 |
| Cancer | A*02:01 | 3720 | ALLTYMIAHI | Thymidylate synthase 231-240 |
| Cancer | A*02:01 | 3721 | ALMDKSLHV | MART-1 56-64 |
| Cancer | A*02:01 | 3722 | ALPPPLMLL | Heparanase 8-16 |
| Cancer | A*02:01 | 3723 | ALSVMGVYV | MAGEA9 223-231 |
| Cancer | A*02:01 | 3724 | ALVEFEDVL | hnRNP L 140-148 |
| Cancer | A*02:01 | 3725 | ALWPWLLMA | RNF43 11-19 |
| Cancer | A*02:01 | 3726 | AMLGTHTMEV | Melanocyte-specific secreted glycoprotein 184-193 |
| Cancer | A*02:01 | 3728 | AVIGALLAV | Melanocyte-specific secreted glycoprotein 20-28 |
| Cancer | A*02:01 | 3730 | CLYGNVEKV | hnRNP L 404-412 |
| Cancer | A*02:01 | 3731 | DLIFGLNAL | Heparanase 185-193 |
| Cancer | A*02:01 | 3732 | ELFQDLSQL | ETV5 54-53 |
| Cancer | A*02:01 | 3733 | FAWERVRGL | Cyclin-dependent kinase inhibitor 1 97-105 |
| Cancer | A*02:01 | 3734 | FIASNGVKLV | ACTN4 118-127 (K5N) |
| Cancer | A*02:01 | 3735 | FLALIICNA | Tubulin beta 4 283-291 |
| Cancer | A*02:01 | 3736 | FLDEFMEGV | Malic enzyme 224-232 |
| Cancer | A*02:01 | 202A | RMFPNAPYL | WT-1 126-134 (Wilms tumor) |
| Cancer | A*02:01 | 543 | ALCNTDSPL | iLR1 |
| Cancer | A*02:01 | 550 | ALKDVEERV | MAGE-C2 336-344 |
| Cancer | A*02:01 | 628 | LLAARAIVAI | iLR1 59-68 |
| Cancer | A*02:01 | 884 | RLWQELSDI | circadian clock protein PASD1 691-700 |
| Cancer | A*02:01 | 1303 | LLFGLALIEV | MAGE-C2 191-200 |
| Cancer | A*02:01 | 2194 | YLNPSVDSV | EWS-FLI-1 oncogene |
| Cancer | A*02:01 | 2282 | FLDPRPLTV | CYP190 |
| Cancer | A*02:01 | 3418 | STLCQVEPV | MPP11 |
| Cancer | A*02:01 | 3419 | VLQMKEEDV | iLR1 |
| Cancer | A*02:01 | 3420 | AIQDLCLAV | NPM1 |
| Cancer | A*02:01 | 3421 | QLLIKAVNL | MPP11 |
| Cancer | A*02:01 | 3422 | AIQDLCVAV | NPM1 |
| Cancer | A*02:01 | 3423 | ALTPVVVTL | cyclin-dependent kinase 4 170-178 |
| Cancer | A*02:01 | KLLPYIVGV | Collagen Type VI Alpha 3 Chain (COL6A3) 414-422 | |
| Cancer | A*02:01 | SLDDYNHLVTL | Dopachrome tautomerase (DCT / TRP-2) 288-298 | |
| Cancer | A*02:01 | LLLDDLLVSI | Peroxiredoxin 5 (PRDX5) 110-119 | |
| Cancer | A*02:01 | SLYKGLLSV | DNA repair and recombination protein RAD54B isoform 1 618-626 | |
| Cancer | A*02:01 | VLLGVKLFGV | Collagen type XVIII alpha-1 chain (COL18A1) | |
| Cancer | A*02:01 | TLDEKVAEL | Melanoma-associated antigen C2 (MAGE-C2) 140-148 | |
| Cancer | A*02:01 | SLMEQIPHL | Cytoskeleton-Associated Protein 2 (CKAP2) | |
| Cancer | A*02:01 | FIADLVVGL | Alpha-enolase (ENO1 / 2-phospho-D-glycerate hydro-lyase) 380-388 | |
| Cancer | A*02:01 | ALWDRVVDL | Alkylglycerone phosphate synthase (AGPS) P559L | |
| Cancer | A*02:01 | LLMDWVNAV | abnormal spindle-like microcephaly-associated (ASPM) 1115-1123 | |
| Cancer | A*02:01 | KLLEYIEEI | Hyaluronan-mediated motility receptor (HMMR / RHAMM / CD168) 232-240 | |
| Cancer | A*02:01 | ALLSGVRQV | Tyrosine hydroxylase (TH) 174-182 | |
| Cancer | A*02:01 | QLLALLPSL | Preferentially Expressed Antigen in Melanoma (PRAME) 394-402 | |
| Cancer | A*02:01 | SLSGVMLTDV | Preferentially Expressed Antigen in Melanoma (PRAME) 355-364 | |
| Cancer | A*02:01 | VLWDYVYQL | Ets variant transcription factor 6 (ETV6) | |
| Cancer | A*02:01 | QLLNSVLTL | Human retroelement-silencing factor 1 (RESF1) 248-256 | |
| Cancer | A*02:01 | AMLVLLAEI | Latent Nuclear Antigen 1 (LANA-1) 281-289 | |
| Cancer | A*02:01 | YLYDRLLRV | GINS complex subunit 1 (GINS1) | |
| Cancer | A*02:01 | HLEEQIAKV | NDC80 kinetochore complex component 599-607 | |
| Cancer | A*02:01 | MLMAQEALAFL | CTL-recognized antigen on melanoma (CAMEL) 1-11 | |
| Cancer | A*02:01 | ALNSEALSVV | TMPRSS2:ERG | |
| Cancer | A*02:01 | SLADTNSLAV | Melanocyte protein PMEL (gp100 or Pmel17) 570-579 | |
| Cancer | A*02:01 | ALLNIKVKL | Keratin, type I cytoskeletal 18 (Keratin-18 or K18) 3650373 | |
| Cancer | A*02:01 | AMFWSVPTV | Human transketolase isoform 1 (TKT) 425-443 | |
| Cancer | A*02:01 | VLLRALPVL | mutated human mitochondrial ribosomal protein (MRPS17) | |
| Cancer | A*02:01 | YISPWILAV | X-box binding protein 1 (XBP1) 184-192 | |
| Cancer | A*02:01 | SLSKILDTV | Ankyrin repeat domain-containing protein 30A (ANKRD30A or NY-BR-1) 904-912 | |
| Cancer | A*02:01 | FLLDGSANV | collagen type VI alpha-3 chain (COL6A3) 642-650 | |
| Cancer | A*02:01 | MLPEELFEL | Galectin-3-binding protein (90K / Gal-3BP) 351-359 | |
| Cancer | A*02:01 | YLHARLREL | Preferentially Expressed Antigen in Melanoma (PRAME) 462-470 | |
| Cancer | A*02:01 | YLSKIIPAL | Replication factor C subunit 5 (RFC5) 157-165 | |
| Cancer | A*02:01 | YLSNIIPAL | replication factor C subunit 5 (RFC5 K160N) neoantigen 157-165 | |
| Cancer | A*02:01 | LIYDSSLCDL | mammaglobin-A (Mam-A) 83-92 | |
| Cancer | A*02:01 | SLQEKVAKA | Hyaluronan-mediated motility receptor (HMMR / RHAMM) 480-488 | |
| Cancer | A*02:01 | LLDTRTLEV | Human telomerase reverse transcriptase (hTERT / Telomerase) 934-942 | |
| Cancer | A*02:01 | FLYNLLTRV | Protein transport protein Sec24A | |
| Cancer | A*02:01 | KLSHQLVLL | Sorting nexin-24 (SNX24) | |
| Cancer | A*02:01 | IMAHCILDL | Human signal recognition particle 9 kDa protein (SRP9) isoform 1 | |
| Cancer | A*02:01 | RLLDSVSRL | Laminin subunit gamma-2 (LAMC2) 850-858 | |
| Cancer | A*02:01 | LLGKDVLFL | Phosphoglycerate kinase 1 (PGK1) 87-95 | |
| Cancer | A*02:01 | RLQESLKKV | Pyridoxal-dependent decarboxylase domain-containing protein 1 (PDXDC1) 366-374 | |
| Cancer | A*02:01 | GLLNSIWPL | Family with sequence similarity 86, member C1 T85I (FAM86C1) | |
| Cancer | A*02:01 | YLYDRLLRI | GINS triad/tetad complex subunit 1 (PSF1 / GINS1) 79-87 | |
| Cancer | A*02:01 | FLIYLDVSV | WD Repeat Domain 46 (WDR46) T300I | |
| Cancer | A*02:01 | FLYNPLTRV | Protein transport protein Sec24A 450-458 | |
| Cancer | A*02:01 | TIDDGIFEV | Heat shock 70 kDa protein 1A (HSPA1A / HSP70-1) 213-221 | |
| Cancer | A*02:01 | ALGALTVWL | zinc finger DHHC-type containing 16 (ZDHHC16) | |
| Cancer | A*02:01 | FLSDHLYLV | CDC37 family co-chaperone-like protein 1 (CDC37L1) P183L | |
| Cancer | A*02:01 | ILTGLNYEV | NAD(P) dependent steroid dehydrogenase-like (NSDHL) A290V | |
| Cancer | A*02:01 | FLAMLKNTV | Cancer/testis antigen 7 (CT7 / MAGE-C1) 1087-1095 | |
| Cancer | A*02:01 | SLDGKAIKV | RNA-binding motif protein, X-linked (RBMX) 73-81 | |
| Cancer | A*02:01 | LLWGHPRVALA | matrix-remodeling associated 5 (MXRA5) 16-26 | |
| Cancer | A*02:01 | ALDGGNKHFL | premature melanoma-associated gp100 (PMEL) 224-233 | |
| Cancer | A*02:01 | LLDGTATLRL | Melanocyte protein PMEL (gp100 / Pmel17) 457-466 | |
| Cancer | A*02:01 | SLTALVFHV | Non-coding 3' untranslated region (3' UTR) translated via alternative or cryptic reading frames | |
| Cancer | A*02:01 | RLDAVLMEV | Myosin regulatory light chain interacting protein (MYLIP or IDOL) | |
| Cancer | A*02:01 | FLLDSCTKL | CCT4.S115F (a mutated variant of the chaperonin containing TCP1 subunit 4 protein) | |
| Cancer | A*02:01 | HIAKSLFEV | Filamin-A (FLNA) 364-372 | |
| Cancer | A*02:01 | LLLGIGILV | Bone marrow stromal cell antigen 2 / Tetherin (HM1.24 / BST2) 22-30 | |
| Cancer | A*02:01 | FLGPWPAAV | Low-density lipoprotein receptor-related protein-associated protein 1 (LRPAP1 or RAP) | |
| Cancer | A*02:01 | AMLERQFTV | Protein N-lysine methyltransferase (METTL21A) 185-193 | |
| Cancer | A*02:01 | KLFPGSPAI | RAN GTPase activating protein 3 domain containing 8 (RGPD8 ) 122-131 | |
| Cancer | A*02:01 | FLMIHLQRV | RAC GTPase-activating protein 1 (RACGAP1) 475-483 | |
| Cancer | A*02:01 | MLGERLFPL | Polyadenylate-binding protein 1 (PABPC1) 556-564 | |
| Cancer | A*02:01 | MLIGIPVYV | ring finger protein 19B (RNF19B) V372L | |
| Cancer | A*02:01 | ELFPQLISV | X-box binding protein 1 (XBP1) 368-376 | |
| Cancer | A*02:01 | ALSDETWGL | Growth factor receptor-bound protein 7 (GRB7) 137-145 | |
| Cancer | A*02:01 | KLVVVGAAGV | KRAS proto-oncogene, GTPase (K-Ras) G12A | |
| Cancer | A*02:01 | GLAPPQHLI | Cellular tumor antigen p53 (TP53) 187-195 | |
| Cancer | A*02:01 | HLYASLSRV | Human mitochondrial ribosomal protein S5 (MRPS5 isoform CRA_b / MRPS5 mutated variant | |
| Cancer | A*02:01 | KVFAGIPTV | Receptor-type tyrosine--protein phosphatase zeta (PTPRZ1) 1333-1341 | |
| Cancer | A*02:01 | CLNEYHLFL | transmembrane protein 48 (TMEM48) 161-169 | |
| Cancer | A*02:01 | ALREEEEGV | Melanoma-Associated Antigen 1 (MAGE-A1) 301-309 | |
| Cancer | A*02:01 | FLLDEAIGL | Speckle-type POZ protein (SPOP) | |
| Cancer | A*02:01 | AMIPKDWPL | Human endogenous retrovirus group K member 113 (HERV-K113) Pol protein 113 - 120 | |
| Cancer | A*02:01 | YLDPAQRGV | Methyltransferase-like protein 26 (METTL26) 21-29 | |
| Cancer | A*02:01 | LLHGFSFYL | Protein-serine O-palmitoleoyltransferase porcupine (PORCN) 339–347 | |
| Cancer | A*02:01 | YLYHRVDVI | Ubiquitin-Specific Peptidase 7 (USP7) D798Y | |
| Cancer | A*02:01 | QLSRELLPV | lipoxygenase homology domain-containing protein 1 (LOXHD1) 1134-1142 | |
| Cancer | A*02:01 | RLIPYDWEI | Gag polyprotein 344-352 | |
| Cancer | A*02:01 | RLFPDFFTRV | Proteinase 3 (PR3) 227-236 | |
| Cancer | A*02:01 | FLPEFGISSA | lens protein with a glutamine synthetase-like domain (Lengsin) 270-279 | |
| Cancer | A*02:01 | YLVYQMLKV | Mitogen-activated protein kinase 13 (MAPK13) G137V | |
| Cancer | A*02:01 | FLTYLDVSV | WD repeat domain 46 (WDR46) 298-306 | |
| Cancer | A*02:01 | KMILKMVQL | Preferentially Expressed Antigen in Melanoma (PRAME) 224-232 | |
| Cancer | A*02:01 | TLAKFSPYL | Preferentially Expressed Antigen in Melanoma (PRAME) 248-256 | |
| Cancer | A*02:01 | AIISGDSPV | Myeloid cell surface antigen CD33 (Siglec-3) 65-73 | |
| Cancer | A*02:01 | KMIGNHLWV | Cyclin-dependent kinase inhibitor 2A (CDKN2A) | |
| Cancer | A*02:01 | TVIGELTSV | Tubulin alpha-1A chain 73-81 | |
| Cancer | A*02:01 | SAMTNLAAL | Prostatic acid phosphatase 115-123 | |
| Cancer | A*02:01 | YIGEVLVSM | Class I myosin heavy chain | |
| Cancer | A*02:01 | AIDAALTFV | Nuclear pore membrane glycoprotein 210 (NUP210) | |
| Cancer | A*02:01 | ALIHHNTYL | Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2 or HER2) H473Y | |
| Cancer | A*02:01 | KLIDCYTFL | Human endogenous retrovirus K (HERV-K provirus / HERV-K) 208-216 | |
| Cancer | A*02:01 | GLDDMKANL | Paired box protein Pax-5 (PAX5) 273-281 | |
| Cancer | A*02:01 | YMFPNAPYL | Wilms' tumor 1 (WT1) 199-207 | |
| Cancer | A*02:01 | KILEKEIRV | hyaluronan-mediated motility receptor (HMMR) 85-93 | |
| Cancer | A*02:01 | TIDDIVLTI | Cation channel sperm-associated protein 4 (CATSPER4) | |
| Cancer | A*02:01 | VLQNVAFSV | Bcl-2-related protein A1 (BCL2A1) 36-44 | |
| Cancer | A*02:01 | MLAVISCAV | tumor-associated T cell epitope derived from the envelope protein of the HERV-K-MEL human endogenous retrovirus | |
| Cancer | A*02:01 | FLDLPEPLL | DEP domain-containing protein 1 (DEPDC1) 283-291 | |
| Cancer | A*02:01 | FLRNFSLMV | T-cell receptor gamma alternate reading frame protein (TARP) 27-35 | |
| Cancer | A*02:01 | TLWCSPIKV | Sushi repeat-containing protein X-linked (SRPX) | |
| Cancer | A*02:01 | FLRNFSLML | T-cell receptor gamma alternate reading frame protein (TARP) 27-35 | |
| Cancer | A*02:01 | FMFQEALKL | Melanoma-associated antigen 9 (MAGE-A9) 102-110 | |
| Cancer | A*02:01 | FLCMKALLL | Androgen Receptor (AR) 805-813 | |
| Cancer | A*02:01 | KLSHQPVLL | Sorting Nexin-24 (SNX24) protein 127-135 | |
| Cancer | A*02:01 | SMPDFDLHL | Neuroblast differentiation-associated protein AHNAK 2580–2588 | |
| Cancer | A*02:01 | HVDGFIANV | receptor tyrosine-protein kinase erbB-3 (HER3 / ErbB-3) 113-121 | |
| Cancer | A*02:01 | KLVVVGAGDV | KRAS G13D | |
| Cancer | A*02:01 | EVIGPDGLITV | Ropporin-1B (ROPN1B) 190-200 | |
| Cancer | A*02:01 | LIMQLMPFGCL | Epidermal Growth Factor Receptor (EGFR) T790M 100-110 | |
| Cancer | A*02:01 | NLSSAEVVV | Insulin-like growth factor II mRNA-binding protein 3 (IMP3) 515-523 | |
| Cancer | A*02:01 | RLFFYRKSV | Human telomerase reverse transcriptase (hTERT) 572-580 | |
| Cancer | A*02:01 | KLMNIQQQL | A-kinase anchor protein 13 (AKAP13) 278-286 | |
| Cancer | A*02:01 | FMPDFDLHL | neuroblast differentiation-associated protein AHNAK | |
| Cancer | A*02:01 | IMQLMPFGCLL | Epidermal Growth Factor Receptor (EGFR) 101-111 | |
| Cancer | A*02:01 | VVVPYEPPEV | Tumor suppressor p53 216-225 | |
| Cancer | A*02:01 | VVVPCEPPEV | Tumor suppressor p53 Y220C 216-225 | |
| Cancer | A*02:01 | YLSFIKILL | Human Endogenous Retrovirus group K (HERV-K) 15-23 | |
| Cancer | A*02:01 | YAMSNLFSI | Human Endogenous Retrovirus group K (HERV-K) 287-295 | |
| Cancer | A*02:01 | FMFVNSLLL | WD repeat-containing protein 75 (WDR75) | |
| Cancer | A*02:01 | QLCDVMFYL | BRCA1-associated protein (BRAP) | |
| Cancer | A*02:01 | ILTGLNYEA | NAD(P)-dependent dehydrogenase/isomerase-like (NSDHL) 282-290 | |
| Cancer | A*02:01 | FLVREDFVL | Cathepsin G 52-60 | |
| Cancer | A*02:01 | SLGDWGAEA | Metalloproteinase inhibitor 3 (TIMP3) 15-23 | |
| Cancer | A*02:01 | FLWGPRALA | Melanoma-associated antigen A4 (MAGE-A4) 272-280 | |
| Cancer | A*02:01 | FLQFKTWWI | Human endogenous retrovirus K (HERV-K) 363-371 | |
| Cancer | A*02:01 | LLLPLLPPLSP | Insulin-like growth factor-binding protein-like 1 (IGFBPL1) 14-24 | |
| Cancer | A*02:01 | SLFEGIDIYT | Heat shock protein 70 family (Hsp70-2 / HSPA1A) F293I | |
| Cancer | A*02:01 | KLVEFDFLGA | Transforming acidic coiled-coil-containing protein 3 (TACC3) 599-608 | |
| Cancer | A*02:01 | ALLPSLSHC | Preferentially Expressed Antigen in Melanoma (PRAME) 397-405 | |
| Cancer | A*02:01 | FVYGEPREL | Melanoma-associated antigen C2 (MAGE-C2) 265-273 | |
| Cancer | A*02:01 | MVIGIPVYV | RNF19B protein 180-188 | |
| Cancer | A*02:01 | YVYQNEHEV | Aldo-keto reductase family 1 member B10 (AKR1B10) 47-55 | |
| Cancer | A*02:01 | QLSCISTYV | Olfactory receptor 8B3 (OR8B3) | |
| Cancer | A*02:01 | GTLEEVPTA | Melanoma-associated antigen 1 (MAGE-A1) 41-49 | |
| Cancer | A*02:01 | FLDRFLSCM | Cyclin-A1 227-235 | |
| Cancer | A*02:01 | CLLWSFQTSA | tyrosinase 8-17 | |
| Cancer | A*02:01 | YLNSGIHSGA | Beta-catenin D32N | |
| Cancer | A*02:01 | AVIDAYTEI | La-related protein 7 isoform 2 LARP7) | |
| Cancer | A*02:01 | QMFFCFKEL | Survivin (Baculoviral IAP repeat-containing protein 5 / BIRC5) | |
| Cancer | A*02:01 | GTIGIFWFV | Sialin isoform 6 (SLC17A5) 234-242 | |
| Cancer | A*02:01 | FLDETLRSLA | GDNF family receptor alpha-2 (GFRA2) 12-21 | |
| Cancer | A*02:01 | FVFLRNFSL | T-cell receptor gamma alternate reading frame protein (TARP) 27-35 | |
| Cancer | A*02:01 | VVAAHLAGA | Cartilage intermediate layer protein 2 (12-20) | |
| Cancer | A*02:01 | RVLHSPPAV | Microtubule Actin Crosslinking Factor 1 (MACF1) 1510-1518 | |
| Cancer | A*02:01 | GVYAGREHFV | Melanoma-associated antigen C2 (MAGE-C2) 257-266 | |
| Cancer | A*02:01 | IMNDMPIYM | Ephrin type-A receptor 2 (EphA2) 58-66 | |
| Cancer | A*02:01 | KLLEIAPNC | truncated large T antigen 15-23 | |
| Cancer | A*02:01 | FVGALSFSI | NPC intracellular cholesterol transporter 1 | |
| Cancer | A*02:01 | ACDPHSGHFV | Cyclin-dependent kinase 4 (CDK4) R24C | |
| Cancer | A*02:01 | AMPFATPMEA | NY-ESO-1 93-102 | |
| Cancer | A*02:01 | KQIDQFLVV | Metastasis-associated protein 1 (MTA1) 122-130 | |
| Cancer | A*02:01 | AMPFSIFYPM | Otopetrin-1 (OTOP1) | |
| Cancer | A*03:01 | 87 | KQSSKALQR | bcr-abl 210 kD fusion protein 21-29 |
| Cancer | A*03:01 | 118 | ALLAVGATK | gp100 (pmel17) 17-25 |
| Cancer | A*03:01 | 264 | ATGFKQSSK | bcr-abl 210 kD fusion protein 259-269 |
| Cancer | A*03:01 | 541 | RISTFKNWPK | Survivin-3A 18-27 (27K) |
| Cancer | A*03:01 | 552 | RLGLQVRKNK | RhoC 176-185 (177L) |
| Cancer | A*03:01 | 615 | RLLFFAPTR | Mcl-1 95-103 |
| Cancer | A*03:01 | 3369 | QVLKKIAQK | HMOX1 145-153 |
| Cancer | A*03:01 | 3370 | RIAAWMATY | 165-173 |
| Cancer | A*03:01 | KLYSEAKTK | Cytotoxic and regulatory T-cell molecule 363-371 | |
| Cancer | A*03:01 | RVSLPKLGYK | CD59 48-57 | |
| Cancer | A*03:01 | RLNAALREK | Receptor for Hyaluronan-Mediated Motility (HMMR) 118-126 | |
| Cancer | A*03:01 | RLWKPQEPK | ||
| Cancer | A*03:01 | RTAGHPLTR | Tyrosine-protein phosphatase non-receptor type 7 (76-84) | |
| Cancer | A*03:01 | LIYRRRLMK | premelanosome protein (Melanocyte protein PMEL) 614-622 | |
| Cancer | A*03:01 | STYPAQNGQVK | Receptor-type tyrosine-protein phosphatase C (PTPRC / CD45) 1227-1237 | |
| Cancer | A*03:01 | RLVELAGQSLLK | Preferentially Expressed Antigen in Melanoma (PRAME) 25-36 | |
| Cancer | A*03:01 | SLHAYIIAK | Protein Tyrosine Phosphatase Receptor Type C / CD45 (PTPRC) 266-274 | |
| Cancer | A*03:01 | ALNFPGSQK | Melanocyte protein PMEL (gp100) 87-95 | |
| Cancer | A*03:01 | ALHGGWTTK | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha H1047L | |
| Cancer | A*03:01 | VLRENTSPK | ErbB-2 receptor tyrosine-protein kinase (HER-2/neu or ERBB-2) 754-762 | |
| Cancer | A*03:01 | HLFGYSWYK | Carcinoembryonic antigen (CEA / CEACAM5) 61-69 | |
| Cancer | A*03:01 | AVASVPIMY | EZH2 (Enhancer of zeste homolog 2) 103-111 | |
| Cancer | A*03:01 | SVMGVYVGK | Melanoma-associated antigen A9 (MAGE-A9) 225-233 | |
| Cancer | A*03:01 | TVYHSPVSR | Protein Regulator of Cytokinesis 1 (PRC1) 509-517 | |
| Cancer | A*03:01 | TSALPIIQK | Perilipin-2 (PLIN2) 63-71 | |
| Cancer | A*03:01 | AAFKRSCLK | large T antigen [Merkel cell polyomavirus] 32-40 | |
| Cancer | A*11:01 | 785 | VVGAVGVGK | KRAS G12V (8-16) |
| Cancer | A*11:01 | 3070 | VVVGADGVGK | KRAS G12D (7-16) |
| Cancer | A*11:01 | 3072 | VVVGAVGVGK | KRAS G12V (7-16) |
| Cancer | A*11:01 | RVWDLPGVLK | centromere protein M isoform c (3-12) | |
| Cancer | A*11:01 | HTMGFWLTK | von Hippel-Lindau tumor suppressor 23-31 | |
| Cancer | A*11:01 | VVVGARGVGK | Kras oncogene protein G12R 7-16 | |
| Cancer | A*11:01 | VVGAGGVGK | Kras oncogene protein 8-16 | |
| Cancer | A*11:01 | VVGARGVGK | Kras oncogene protein G12R 8-16 | |
| Cancer | A*11:01 | SSYTGFANK | Kinesin Family Member 26B (KIF26B) 254-263 | |
| Cancer | A*11:01 | ASNAPSAAK | probable E3 ubiquitin-protein ligase (HERC1) 3274-3282 | |
| Cancer | A*11:01 | SVLKPGNSK | E74-like factor 1 (ELF1) | |
| Cancer | A*11:01 | ASNASSAAK | Probable E3 ubiquitin-protein ligase (HERC1) S3278S | |
| Cancer | A*11:01 | SVSKLSTPK | Zinc finger and BTB domain-containing protein 1 (ZBTB1) 197-205 | |
| Cancer | A*11:01 | RSGGFSFGK | large T antigen, partial [Merkel cell polyomavirus] 95-103 | |
| Cancer | A*11:01 | TVLKPGNSK | E74-like factor 1 (ELF1) 319-327 | |
| Cancer | A*11:01 | AIKTSPKANK | Epidermal Growth Factor Receptor (EGFR) | |
| Cancer | A*11:01 | ALIVFWKYR | Kita-kyushu lung cancer antigen 1 (KK-LC-1) 14-22 | |
| Cancer | A*11:01 | ALNFPGSQK | Melanocyte protein PMEL 87-95 | |
| Cancer | A*24:02 | 209 | TYACFVSNL | Carcinogenic Embryonic Antigen (CEA) 652-660 |
| Cancer | A*24:02 | 230 | AFLPWHRLF | Tyrosinase 188-196 |
| Cancer | A*24:02 | 237 | IMPKAGLLI | MAGE-A3 |
| Cancer | A*24:02 | 238 | VYFFLPDHL | gp100-intron 4 (170-178) |
| Cancer | A*24:02 | 416 | EYLQLVFGI | MAGEA2 156-164 |
| Cancer | A*24:02 | 417 | TYLPTNASL | HER-2/neu 63-71 |
| Cancer | A*24:02 | 418 | VYGFVRACL | Telomerase reverse transcriptase (hTRT) 461-469 |
| Cancer | A*24:02 | 421 | TFPDLESEF | MAGEA3 97-105 |
| Cancer | A*24:02 | 1064 | DYLQYVLQI | MiHA ACC1 15-23 |
| Cancer | A*24:02 | 1806 | RYCNLEGPPI | Lymphocyte antigen 6 complex locus K (LY6K) 177-186 |
| Cancer | A*24:02 | 2302 | AYACNTSTL | Survivin 80-88 |
| Cancer | A*24:02 | 2303 | CYASGWGSI | Prostate Specific Antigen-1 153-161 |
| Cancer | A*24:02 | 3351 | DYLNEWGSRF | CDH3 807-816 |
| Cancer | A*24:02 | 3353 | EYCPGGNLF | MELK 87-95 (93N) |
| Cancer | A*24:02 | 3354 | EYYELFVNI | DEP DC1 294-302 |
| Cancer | A*24:02 | 3360 | GYCTQIGIF | HENMT1 221-229 |
| Cancer | A*24:02 | 3362 | IYTWIEDHF | FOXM1 262-270 |
| Cancer | A*24:02 | 3367 | NYQPVWLCL | RNF43 721-729 (722Y) |
| Cancer | A*24:02 | 3372 | RYNAQCQETI | Midkine 110-119 |
| Cancer | A*24:02 | 3380 | EYRALQLHL | CA9 219-227 |
| Cancer | A*24:02 | 3382 | SYRNEIAYL | TTK protein kinase 551-559 |
| Cancer | A*24:02 | 3384 | VYLRVRPLL | KIF20A 67-75 |
| Cancer | A*24:02 | 3385 | VYYNWQYLL | IL13r 146-154 |
| Cancer | A*24:02 | SYQKVIELF | T-lymphokine-activated killer cell-originated protein kinase (TOPK) 289-297 | |
| Cancer | A*24:02 | LYPEFIASI | DPY19-like protein 4 (DPY19L4) L143F | |
| Cancer | A*24:02 | IYLDLPWYL | Toll-like receptor 1 (TLR1) S602I | |
| Cancer | A*24:02 | IYPDITYSL | Cholinergic Receptor Nicotinic Alpha 3 (CHRNA3) 227-235 | |
| Cancer | A*24:02 | IYPQVLHSL | E3 ubiquitin-protein ligase RNF213 (Ring finger protein 213) 3834-3842 | |
| Cancer | A*24:02 | TYSPALNKMF | Cellular tumor antigen p53 125-134 | |
| Cancer | A*24:02 | RYYVGHKGKF | Protein mago-nashi homolog 2 / B (MAGOHB) 10-19 | |
| Cancer | A*24:02 | RYYVGHKAKF | Protein mago-nashi homolog 2 / B (MAGOHB) G17A 10-19 | |
| Cancer | A*24:02 | DYGMIDESI | cancer/testis antigen CT55 49-57 | |
| Cancer | A*24:02 | QYSPVQATF | coenzyme A synthase (COASY S55Y) | |
| Cancer | A*24:02 | LYAPYSTHF | G protein-coupled receptor class C group 5 member A (GPRC5A) 316-324 | |
| Cancer | A*24:02 | PYVSRLLGI | Receptor tyrosine-protein kinase erbB-2 (HER2/neu) 780-788 | |
| Cancer | A*24:02 | SYNPLWLRI | abnormal spindle-like microcephaly-associated (ASPM) 818-826 | |
| Cancer | A*24:02 | KWLISPVKI | Holliday junction recognition protein (HJURP) 408-416 | |
| Cancer | A*24:02 | LYAPTILLW | Alpha-fetoprotein (AFP) 173-181 | |
| Cancer | A*24:02 | MWITQCFLPVF | Cancer/testis antigen 1 (NY-ESO-1) 160-170 | |
| Cancer | A*29:02 | 3397 | KEKYIDQEEL | HSP90 alpha 280-288 (Pathologic Conditions) |
| Cancer | A*68:01 | 3398 | TVSGNILTIR | NY-ESO-1 127-136 |
| Cancer | B*07:02 | 2304 | LPWHRLFLL | Tyrosinase 208-216 |
| Cancer | B*07:02 | 2369 | EPR(PHOSPHO-S)PSHSM | KMT2A / pMLL 747-755 |
| Cancer | B*07:02 | 3239 | TPNQRQNVC | P2X5 |
| Cancer | B*07:02 | 3348 | APRGVRMAV | LAGE-1 46-54 |
| Cancer | B*07:02 | 3364 | LPVSPRLQL | CEACAM 185-193 |
| Cancer | B*07:02 | PPSGLRLLPL | Transforming growth factor beta-1 proprotein (TGF-β1) 2-11 | |
| Cancer | B*07:02 | RPRLGNRPSL | lymphoblastoid cell line (GR-LCL) | |
| Cancer | B*07:02 | APLPRPGAVL | Cancer/Testis Antigen 2 / LAGE-1 (CTAG2) 114-123 | |
| Cancer | B*07:02 | KPRPDVTNEL | Cell division cycle-associated protein 7 (CDCA7) 94-103 | |
| Cancer | B*07:02 | RPPPPPAWL | Lysine-specific demethylase 6B (KDM6B) 478-486 | |
| Cancer | B*07:02 | APNCYGNIPL | T-antigen (LTA) of the Merkel cell polyomavirus 20-29 | |
| Cancer | B*07:02 | GPRMQLCTQL | RING finger protein 43 (RNF43) | |
| Cancer | B*07:02 | SPVTEIRTDL | Partner and localizer of BRCA2 (PALB2) | |
| Cancer | B*07:02 | KPSDTPRPVM | Mixed-Lineage Leukemia protein 3 / Histone-lysine N-methyltransferase (MLL3 or KMT2C) | |
| Cancer | B*07:02 | FPSLREAAL | Melanoma-associated antigen 1 (MAGE-A1) 294-302 | |
| Cancer | B*07:02 | MPMQDIKMIL | Preferentially Expressed Antigen in Melanoma (PRAME) 218-227 | |
| Cancer | B*07:02 | IPQQHTQVL | Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) 632-640 | |
| Cancer | B*07:02 | NPRYPNYMF | Tyrosine-protein kinase transmembrane receptor (ROR1) 783-791 | |
| Cancer | B*07:02 | RPILTIITL | Cellular tumor antigen p53 210-218 | |
| Cancer | B*07:02 | KPFCVLISL | DOPEY2 | |
| Cancer | B*07:02 | RPHHDQRSL | Human tau-tubulin kinase 2 (TTBK2) S1181L | |
| Cancer | B*07:02 | GADGVGKSAL | KRAS G12D | |
| Cancer | B*07:02 | RVRFFFPSL | Melanoma-associated antigen 1 (MAGE-A1) 289-297 | |
| Cancer | B*07:02 | RVAGSMSSL | Roundabout homolog 3 (ROBO3) | |
| Cancer | B*08:01 | 94 | GFKQSSKAL | bcr-abl 210 kD fusion protein 19-27 |
| Cancer | B*08:01 | ESKIRVLL | Hyaluronan-mediated motility receptor (HMMR) 73-80 | |
| Cancer | B*08:01 | APLLRWVL | Heme oxygenase 1 (HMOX1 / HO-1) 265-272 | |
| Cancer | B*27:05 | 424 | GRFGLATEK | BRAF 594-601 (600E) |
| Cancer | B*27:05 | 3359 | GRFGLATVK | BRAF 594-601 (600V) |
| Cancer | B*27:05 | 202B | RMFPNAPYL | WT-1 126-134 (Wilms tumor) |
| Cancer | B*27:05 | RREDVVLGR | T-cell leukemia/lymphoma protein 1A (TCL1A) 52-60 | |
| Cancer | B*35:01 | 2307 | MPFATPMEA | NY-ESO-1 94-102 |
| Cancer | B*35:01 | MPFATPMEAEL | cancer-testis antigen NY-ESO-1 (LAGE-2) 94-104 | |
| Cancer | B*35:01 | FSFGKAYEY | Large T antigen 99-107 | |
| Cancer | H-2Db | 1731 | ATFKNWPFL | Murine Survivin 20-28 |
| Cancer | H-2Db | 2415 | YSSDNLYQM | Wilms Tumor protein (221- 229) |
| Cancer | H-2Db | 231 | CMTWNQMNL | WT1 235-243 |
| Cancer | H-2Db | 559 | HCIRNKSVI | PSA 65-73 |
| Cancer | H-2Db | 695 | Abu-Abu-L-Abu-LTVFL | Moloney murine sarcoma virus (MoMSV) GagL 85-93 |
| Cancer | H-2Db | 1333 | KVPRNQDWL | gp100 (pmel17) 25-33 |
| Cancer | H-2Db | 1780 | HCIRNKSVIL | hPSA |
| Cancer | H-2Db | 2198 | VILTNPISM | VEGFR2 400-408 |
| Cancer | H-2Db | 2199 | FSNSTNDILI | VEGFR2/KDR fragment 1 614-624 |
| Cancer | H-2Db | 2675 | STHVNHLHC | Endophilin-B2 244-252 |
| Cancer | H-2Db | 2695 | ASMTNMELM | MC-38 Adpgk neoantigen |
| Cancer | H-2Db | 2755 | AQLANDVVL | MC-38 |
| Cancer | H-2Db | 3349 | ASFRNLTHL | TPBG 258-266 |
| Cancer | H-2Db | 202C | RMFPNAPYL | WT-1 126-134 (Wilms tumor) |
| Cancer | H-2Db | NAVGNPEYL | Epidermal growth factor receptor (EGFR) 1131-1139 | |
| Cancer | H-2Db | ASMTNRELM | ADP-dependent glucokinase isoform 1 precursor 299-307 | |
| Cancer | H-2Db | AALLNSAVL | Immunity-related GTPase family Q protein-like (Irgq) | |
| Cancer | H-2Db | SSMHNALHI | Tyrosinase 360–368 | |
| Cancer | H-2Db | AQLPNDVVL | RalBP1-associated Eps domain-containing protein 1 (Reps1) 42-50 | |
| Cancer | H-2Db | YGFRNVVHI | Heat shock factor 2 (Hsf2) 68-76 | |
| Cancer | H-2Db | SSISNFQAV | Interferon-inducible/activated gene family (Ifi203a) 260-268 | |
| Cancer | H-2Db | TQNVNQAKM | melanoma-associated antigen D1 (MAGE-D1) 196-204 | |
| Cancer | H-2Db | SSPYSLHYL | Copine-1 (Cpne1) | |
| Cancer | H-2Db | MAPIDHTTM | apoptosis-antagonizing transcription factor AATF 493-501 | |
| Cancer | H-2Db | IGISNYPESTI | 53BP1 protein 924-934 | |
| Cancer | H-2Db | SAIRSYQYV | Spire1 | |
| Cancer | H-2Dd | TGAARFDEF | General transcription factor IIB | |
| Cancer | H-2Kb | 351 | HNTQYCNL | MAGEA5 5-12 |
| Cancer | H-2Kb | 2311 | TVSEFLKL | Murine Survivin 97-104 |
| Cancer | H-2Kb | 185 | SVYDFFVWL | Tyrosinase related protein-2 180-188 |
| Cancer | H-2Kb | 2585 | VGRNFTNL | mTERT |
| Cancer | H-2Kb | 2754 | SIIVFNLL | MC-38 |
| Cancer | H-2Kb | 3373 | SDYYFSWL | muFAP 289-296 |
| Cancer | H-2Kb | 3376 | SKYVFENV | Mybpc2 295-302 |
| Cancer | H-2Kb | LGYDYSYL | mouse tyrosinase 445–452 | |
| Cancer | H-2Kb | HIYEFPQL | Protein unc-119 homolog B 203-210 | |
| Cancer | H-2Kb | RSYRYKLL | Metalloreductase STEAP1 186-193 | |
| Cancer | H-2Kb | KMYQYARL | RIO kinase 1 (RIOK1) G946T | |
| Cancer | H-2Kb | QVYRFLGV | thyroglobulin precursor 2223-2230 | |
| Cancer | H-2Kb | ATLVFHNL | Signal transducer and activator of transcription 3 (STAT3) 53-60 | |
| Cancer | H-2Kb | ATQQFQQL | gPr80 glycosylated envelope polyprotein 500-508 | |
| Cancer | H-2Kb | KILTFDRL | 60S ribosomal protein L18 (Rpl18) 119-126 | |
| Cancer | H-2Kb | SNPTYSVM | Polyomavirus middle-T (PyMT) antigen 246-253 | |
| Cancer | H-2Kb | SIIVFNLV | GlcNAc-1-P transferase 206-213 | |
| Cancer | H-2Kb | APNCYGNI | Merkel cell polyomavirus (MCPyV) large T antigen 20-27 | |
| Cancer | H-2Kd | SYGVTVWEL | Receptor tyrosine-protein kinase erbB-2 (HER2/neu) 907-915 | |
| Cancer | H-2Kd | SYMAPSTVL | Ubiquinol-cytochrome c reductase core protein II (UQCRC2) | |
| Cancer | H-2Kd | KYSEVFEAI | Casein kinase II subunit alpha (Csnk2a1) 50-58 | |
| Cancer | H-2Kd | SFYDVKGDL | Guanylate cyclase 2c (GUCY2C) 254-262 | |
| Cancer | H-2Kd | KFKASRASI | Neoantigen CT26 mouse colon tumor cell line model | |
| Cancer | H-2Kd | 343 | TYVPANASL | Neu/Her-2/Erbb2 proto-oncoprotein 66-74 |
| Cancer | H-2Kd | 485 | AYIDFEMKI | SART3 315-323 |
| Cancer | H-2Kd | 814 | EYILSLEEL | GPC3 298-306 |
| Cancer | H-2Kd | 3381 | SYMLQALCI | TNPO3 |
| Cancer | H-2Ld | 150 | LPYLGWLVF | Tumour Antigen P815 35-43 |
| Chagas | A*02:01 | TLEEFSAKL | Kinetoplastid Membrane Protein-11 (KMP-11) 4-12 | |
| Chagas | A*02:01 | RLYKTLGQL | Major paraflagellar rod protein 2 (PFR2) 449-457 | |
| Chagas | A*02:01 | ALRNLRVFL | Surface Antigen 2 (TcCA-2) 607-615 | |
| Chagas | A*02:01 | FVSCCGELTV | Trypanosoma cruzi Paraflagellar rod component 3 (putative PFR3) 428–436 | |
| Chagas | A*02:01 | TVFDASRSTV | Trypanosoma cruzi surface antigen TcCA-2 (Surface antigen 2) 1077-1086 | |
| Chlamydia | A*02:01 | 334 | RLNMFTPYI | Chlamydia trachomatis MOMP 258-266 |
| Chlamydia | A*02:01 | 335 | NMFTPYIGV | MOMP precursor 283-291 |
| Chlamydia | B*27:05 | 3094 | ARKLLLDNL | PqqC-like protein 70-78 |
| Chlamydia | B*27:05 | 3945 | NRAKQVIKL | Probable ATP-dependent Clp protease ATP-binding subunit 7-15 |
| Chlamydia | B*27:05 | KRLAETLAL | CT589 67-75 | |
| Chlamydia | H-2Db | 3943 | ASFVNPIYL | Cysteine-rich membrane protein 63-71 |
| Chlamydia | H-2Db | 3947 | SAVSNLFYV | POMP 612-620 |
| CMV | A*01:01 | 266 | YSEHPTFTSQY | HCMV pp65 363-373 |
| CMV | A*01:01 | 739 | VTEHDTLLY | HCMV pp50 245-253 |
| CMV | A*02:01 | 8 | NLVPMVATV | HCMV pp65 495-504 |
| CMV | A*02:01 | 144 | VLEETSVML | HCMV IE1 316-324 (UL123) |
| CMV | A*02:01 | 1598 | VLAELVKQI | HCMV IE1 81-89 |
| CMV | A*02:01 | 2205 | MLNIPSINV | pp65 120-128 |
| CMV | A*02:01 | NLVPPVATV | Lower matrix phosphoprotein pp65 (UL83) 495-503 | |
| CMV | A*02:01 | NLVGMVATV | Phosphoprotein 65 (pp65 / UL83) 495-503 | |
| CMV | A*02:01 | NLVPMVGTV | Lower matrix phosphoprotein pp65 495-503 | |
| CMV | A*02:01 | QMWQARLTV | Phosphoprotein 65 (pp65 / UL83) 155-163 | |
| CMV | A*02:01 | YILEETSVM | Immediate-early protein 1 (IE-1) 315-323 | |
| CMV | A*03:01 | 1599 | KLGGALQAK | HCMV IE1 184-192 |
| CMV | A*24:02 | 380 | VYALPLKML | HCMV pp65 113-121 |
| CMV | A*24:02 | 414 | QYDPVAALF | HCMV pp65 341-349 |
| CMV | A*24:02 | 3390 | AYAQKIFKI | CMV IE-1 248-256 |
| CMV | A*24:02 | AYAQKIFKIL | Immediate-early protein 1 (IE1) 248-257 | |
| CMV | B*07:02 | 45 | TPRVTGGGAM | HCMV pp65 417-426 |
| CMV | B*07:02 | 308 | RPHERNGFTVL | HCMV pp65 265-275 |
| CMV | B*08:01 | 127 | ELRRKMMYM | IE1 199-207 |
| CMV | B*08:01 | 3391 | ELKRKMIYM | CMV IE-1 199-207 (R/L Position 3, M/I Position 7) |
| CMV | B*08:01 | SPRSRLQQL | Immediate-early protein 2 (IE2) 1151-1159 | |
| CMV | B*08:01 | ELNRKMIYM | Immediate-early protein 1 (IE-1) 51-59 | |
| CMV | B*35:01 | 114 | IPSINVHHY | HCMV pp65 123-131 |
| CMV | C*06:02 | 3264 | TRATKMQVI | pp65 211-219 |
| CMV | C*06:02 | 3744 | QIKVRVDM | IE1 88-95 |
| CMV | C*07:02 | 3269 | CRVLCCYVL | IE1 309-317 |
| CMV | H-2Db | 2313 | HGIRNASFI | MCMV m45 985-993 |
| CMV | H-2Dd | 278 | AGPPRYSRI | MCMV m164 257-265 |
| CMV | H-2Dd | 2167 | LGPISGHVL | pp65 15-23 |
| CMV | H-2Kb | 1915 | TVYGFCLL | MCMV M139 419-426 |
| CMV | H-2Kd | 3412 | CYYASRTKL | MCMV m145 451-459 |
| CMV | H-2Ld | 21 | YPHFMPTNL | MCMV IE1 168-176 |
| COVID-19 / SARS-CoV-2 | A*01:01 | 4355 | FTSDYYQLY | SARS-CoV-2 ORF3a 207-215 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*01:01 | 4381 | TTDPSFLGRY | SARS-CoV-2 Replicase polyprotein 1ab 1637-1646 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*01:01 | 4382 | PTDNYITTY | SARS-CoV-2 Replicase polyprotein 1ab 1621-1629 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*01:01 | 4501 | CTDDNALAYY | SARS-Cov-2 ORF1ab 4163-4172 |
| COVID-19 / SARS-CoV-2 | A*01:01 | 4690 | HTTDPSFLGRY | SARS-CoV-2 ORF1ab 1641-1651 |
| COVID-19 / SARS-CoV-2 | A*01:01 | 4726 | IVDTVSALVY | SARS-CoV-2 ORF1ab 5781-5789 |
| COVID-19 / SARS-CoV-2 | A*01:01 | CTDDNALAY | Replicase polyprotein 1ab 4163-4172 | |
| COVID-19 / SARS-CoV-2 | A*01:01 | GTDLEGNFY | Replicase polyprotein 1ab 3437-3445 | |
| COVID-19 / SARS-CoV-2 | A*01:01 | VTPSGTWLTY | nucleocapsid phosphoprotein 324-333 | |
| COVID-19 / SARS-CoV-2 | A*01:01 | DTDFVNEFY | Replicase polyprotein 1ab 5130-5138 | |
| COVID-19 / SARS-CoV-2 | A*01:01 | WTAGAAAYY | surface glycoprotein 258-266 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4320 | LLLDRLNQL | SARS-CoV Nucleocapsid protein 223-231 (conserved in SARS-CoV-2) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4321 | FIAGLIAIV | SARS-CoV-2 Spike glycoprotein 1220-1228 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4322 | ALNTLVKQL | SARS-CoV Spike glycoprotein precursor 940-948 (conserved in SARS-CoV-2) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4323 | LITGRLQSL | SARS-CoV-2 Spike glycoprotein 996-1004 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4324 | NLNESLIDL | SARS-CoV Spike glycoprotein precursor 1174-1182 (conserved in SARS-Cov-2) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4326 | VLNDILSRL | SARS-CoV Spike glycoprotein precursor 958-966 (conserved in SARS-Cov-2) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4339 | YLQPRTFLL | SARS-Cov-2 Spike glycoprotein 269-277 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4342 | LLYDANYFL | SARS-CoV-2 ORF3a 139-147 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4358 | RLQSLQTYV | SARS-CoV-2 Spike glycoprotein 1000-1008 (confirmed subdominant epitope) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4418 | KLWAQCVQL | SARS-CoV-2 ORF1ab 3886-3894 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4725 | TLVPQEHYV | SARS-CoV-2 ORF1ab 5563-5571 |
| COVID-19 / SARS-CoV-2 | A*02:01 | 4340 | KIADYNYKL | SARS-CoV-2 Spike glycoprotein 417-425 |
| COVID-19 / SARS-CoV-2 | A*02:01 | LLLLDRLNQL | Nucleoprotein 221-230 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | KLSYGIATV | Replicase polyprotein 1ab (pp1ab) / ORF1ab 5470-5478 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | ALSKGVHFV | Open Reading Frame 3a (ORF3a) 72–80 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | SMWALVISV | Replicase polyprotein 1ab / pp1a 3661-3669 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | YLNTLTLAV | non-structural protein 16 (NSP16) 53-61 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | VLAWLYAAV | Replicase polyprotein 1ab (ORF1ab non-structural region) 3467-3475 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | KLLEQWNLV | Membrane (M) structural glycoprotein 15–23 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | FLNGSCGSV | Replicase polyprotein 1ab (ORF1ab / pp1ab) 3403–3411 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | GLMWLSYFV | membrane (M) protein 89-97 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | RLANECAQV | RNA-dependent RNA polymerase (RdRp) ORF1ab 5046-5054 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | VLWAHGFEL | ORF1ab polyprotein / Non-structural protein 14 (nsp14-ExoN) 6109-6117 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | HLVDFQVTI | Accessory protein ORF6 3–11 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | ILFTRFFYV | Replicase polyprotein 1ab / pp1a (ORF1ab region) 2332-2340 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | SLVKPSFYV | Envelope (E) protein 50-58 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | ALYYPSARI | Replicase polyprotein ORF1ab 5620-5628 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | GLALYYPSA | Replicase polyprotein 1ab 5618-5626 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | KIYSKHTPI | Spike (S) glycoprotein 202-210 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | SMWSFNPET | Membrane (M) structural 108-116 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | RTIKVFTTV | ORF1ab 1566-1574 | |
| COVID-19 / SARS-CoV-2 | A*02:01 | YTVSCLPFT | ORF8 protein 79-87 | |
| COVID-19 / SARS-CoV-2 | A*03:01 | 4443 | KCYGVSPTK | SARS-CoV-2 Spike glycoprotein 378-386 |
| COVID-19 / SARS-CoV-2 | A*03:01 | 4724 | KLFAAETLK | SARS-CoV-2 ORF1ab 5455-5463 |
| COVID-19 / SARS-CoV-2 | A*03:01 | 4356A | KTFPPTEPK | SARS-CoV-2 Nucleocapsid protein 362-370 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*03:01 | 4691A | VTNNTFTLK | SARS-CoV-2 ORF1ab 808-816 |
| COVID-19 / SARS-CoV-2 | A*03:01 | 4679A | SVYAWNRKR | SARS-CoV-2 Spike glycoprotein 349-357 |
| COVID-19 / SARS-CoV-2 | A*03:01 | KTIQPRVEK | Replicase polyprotein 1a 282-290 | |
| COVID-19 / SARS-CoV-2 | A*03:01 | VVYRGTTTYK | Replicase polyprotein 1ab 5533-5542 | |
| COVID-19 / SARS-CoV-2 | A*03:01 | RIAGHHLGR | Membrane (M) glycoprotein 150-158 | |
| COVID-19 / SARS-CoV-2 | A*03:01 | KVFRSSVLH | Spike (S) glycoprotein 41-49 | |
| COVID-19 / SARS-CoV-2 | A*03:01 | QIYKTPPIK | Spike (S) glycoprotein 787–795 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | 4356B | KTFPPTEPK | SARS-CoV-2 Nucleocapsid protein 362-370 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | A*11:01 | 4691B | VTNNTFTLK | SARS-CoV-2 ORF1ab 808-816 |
| COVID-19 / SARS-CoV-2 | A*11:01 | 4679B | SVYAWNRKR | SARS-CoV-2 Spike glycoprotein 349-357 |
| COVID-19 / SARS-CoV-2 | A*11:01 | STFNVPMEK | Replicase polyprotein 1ab 2600-2608 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | ATEGALNTPK | Nucleocapsid (N) phosphoprotein 134–143 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | ATSRTLSYYK | Membrane (M) structural protein 171–180 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | VTYVPAQEK | Spike (S) glycoprotein 1065-1073 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | GVYYHKNNK | Spike (S) glycoprotein 142-150 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | TLKSFTVEK | Spike (S) glycoprotein 302-310 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | GTHWFVTQR | Spike (S) glycoprotein 1099-1107 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | KSAAEASKK | Nucleocapsid (N) structural protein 249-257 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | NSASFSTFK | Spike (S) glycoprotein 370-378 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | MTSCCSCLK | Spike (S) glycoprotein 1219-1227 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | RLFRKSNLK | surface glycoprotein 454-462 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | LSYFIASFR | Membrane (M) glycoprotein 93-101 | |
| COVID-19 / SARS-CoV-2 | A*11:01 | SAFAMMFVK | Replicase polyprotein 1ab 3622-3630 | |
| COVID-19 / SARS-CoV-2 | A*24:02 | 4668 | QYIKWPWYI | SARS-CoV-2 Spike glycoprotein 1205-1213 |
| COVID-19 / SARS-CoV-2 | A*24:02 | 4670 | VYIGDPAQL | SARS-CoV-2 ORF1ab 5724-5732 |
| COVID-19 / SARS-CoV-2 | A*24:02 | 4692 | NYNYLYRLF | SARS-CoV-2 Spike glycoprotein 448-456 |
| COVID-19 / SARS-CoV-2 | A*24:02 | NYMPYFFTL | orf1ab polyprotein 2167-2175 | |
| COVID-19 / SARS-CoV-2 | A*24:02 | TYACWHHSI | ORF1ab polyprotein 6148-6156 | |
| COVID-19 / SARS-CoV-2 | A*24:02 | VYFLQSINF | ORF3a 112-120 | |
| COVID-19 / SARS-CoV-2 | A*24:02 | QFAPSASAFF | Nucleocapsid (N) protein 306-315 | |
| COVID-19 / SARS-CoV-2 | A*24:02 | KWPWYIWLGF | Spike (S) glycoprotein 1211–1220 | |
| COVID-19 / SARS-CoV-2 | A*68:01 | ASAFFGMSR | Nucleocapsid (N) phosphoprotein 311-319 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | 4351 | SPRWYFYYL | SARS-CoV-2 Nucleocapsid protein 105-113 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | B*07:02 | 4694 | RARSVSPKL | SARS-CoV-2 ORF7a 78-86 |
| COVID-19 / SARS-CoV-2 | B*07:02 | IPRRNVATL | Replicase polyprotein 1ab (ORF1ab) 5916–5924 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | APSASAFFGM | Nucleocapsid phosphoprotein 308-317 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | FPRGQGVPI | Nucleocapsid 66-74 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | KPRQKRTAT | Nucleocapsid 257-265 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | YPDKVFRSSV | Spike glycoprotein 38-47 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | LPKEITVAT | Membrane (M) glycoprotein 164-172 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | LPVSMTKTSV | Spike glycoprotein 727-736 | |
| COVID-19 / SARS-CoV-2 | B*07:02 | IPTNFTISV | surface glycoprotein 714-722 | |
| COVID-19 / SARS-CoV-2 | B*08:01 | DLKGKYVQI | Replicase polyprotein 1ab 4344-4352 | |
| COVID-19 / SARS-CoV-2 | B*27:05 | 4354 | QRNAPRITF | SARS-CoV-2 Nucleocapsid protein 9-17 |
| COVID-19 / SARS-CoV-2 | B*35:01 | IPFAMQMAY | spike (S) glycoprotein 896–904 | |
| COVID-19 / SARS-CoV-2 | B*35:01 | LPFNDGVYF | surface glycoprotein 84-92 | |
| COVID-19 / SARS-CoV-2 | B*40:01 | 4328 | MEVTPSGTWL | SARS-CoV-2 Nucleocapsid protein 322-330 (confirmed epitope) |
| COVID-19 / SARS-CoV-2 | H-2Kb | 4549 | SIIAYTMSL | SARS-CoV-2 Spike glycoprotein 691-699 |
| COVID-19 / SARS-CoV-2 | H-2Kb | 4544 | VVLSFELL | SARS-CoV-2 Spike glycoprotein 505-523 |
| COVID-19 / SARS-CoV-2 | H-2Kd | IYQAGSTPC | Spike glycoprotein 466-485 | |
| COVID-19 / SARS-CoV-2 | H-2Ld | FPQSAPHGV | Spike glycoprotein 1052-1060 | |
| Dengue | A*02:01 | 2929 | TLYAVATTI | Dengue NS4b 40-48 |
| Dengue | A*02:01 | 3931 | KLAEAIFKL | Dengue NS5 563-571 |
| Dengue | A*02:01 | 3914 | ILIRTGLLVI | Dengue NS2b 97-106 |
| Dengue | A*02:01 | 3918 | AIKRGLRTL | Dengue NS3 112-120 |
| Dengue | A*02:01 | 3923 | LLLGLMILL | Dengue NS4a 56-64 |
| Dengue | A*02:01 | 3928 | VLLLVTHYA | Dengue NS4b 111-119 |
| Dengue | A*02:01 | VTLLCLIPTV | Capsid (C) protein 102-111 | |
| Dengue | A*02:01 | NIQTAINQV | Non-structural protein 4B (NS4B DENV serotypes 1, 2, and 3) 3353-3361 | |
| Dengue | A*03:01 | 3913 | ELERAADVK | Dengue NS2b 52-60 |
| Dengue | A*03:01 | 3910A | RVSTVQQLTK | Dengue C 22-31 |
| Dengue | A*03:01 | 3916A | RIEPSWADVK | Dengue NS3 64-74 |
| Dengue | A*03:01 | 3921A | RVIDPRRCMK | Dengue NS3 422-431 |
| Dengue | A*03:01 | 3929A | KITAEWLWK | Dengue NS5 375-383 |
| Dengue | A*03:01 | CVYNMMGKR | Genome polyprotein DENV 4 2937-2945 | |
| Dengue | A*11:01 | 1843 | GTSGSPIINR | Dengue NS3 serotype 3&4 133-142 |
| Dengue | A*11:01 | 2372 | GTSGSPIIDK | Dengue NS3 133-142 |
| Dengue | A*11:01 | 2373 | GTSGSPIVNR | NS3 serotype 1 133-142 |
| Dengue | A*11:01 | 3459 | ATYGWNLVK | DENV 1 NS5 2610-2618 |
| Dengue | A*11:01 | 3460 | STYGWNIVK | DENV 3 NS5 2607-2615 |
| Dengue | A*11:01 | 3461 | STYGWNLVR | DENV 2 NS5 2608-2616 |
| Dengue | A*11:01 | 3906 | GTSGSPIVDR | Dengue NS3 serotype 2 133-142 |
| Dengue | A*11:01 | 3907 | GTSGSPIADK | Dengue NS3 133-142 |
| Dengue | A*11:01 | 4625 | GTSGSPIVDK | DENV 2 NS3 1608-1617 |
| Dengue | A*11:01 | 4626 | GTSGSPIINK | DENV 4 NS3 1607-1617 |
| Dengue | A*11:01 | 4627 | TIPPTAGILK | DENV 2 Core 58-67 |
| Dengue | A*11:01 | 4628 | TTLSRTSKK | DENV 2 NS2a 1336-1344 |
| Dengue | A*11:01 | 4629 | KTFDSEYVK | DENV 2 Polyprotein 1863-1871 |
| Dengue | A*11:01 | 4630 | KTFDSEYIK | DENV 2 NS3 1863-1871 |
| Dengue | A*11:01 | 4631 | KTFDTEYQK | DENV 1 NS3 1864-1872 |
| Dengue | A*11:01 | 4632 | ATVLMGLGK | DENV 2 Polyprotein 2315-2323 |
| Dengue | A*11:01 | 3910B | RVSTVQQLTK | Dengue C 22-31 |
| Dengue | A*11:01 | 3916B | RIEPSWADVK | Dengue NS3 64-74 |
| Dengue | A*11:01 | 3921B | RVIDPRRCMK | Dengue NS3 422-431 |
| Dengue | A*11:01 | 3929B | KITAEWLWK | Dengue NS5 375-383 |
| Dengue | A*24:02 | 2954 | QYSDRRWCF | Dengue NS3 557-565 (Singapore/S275/1990) |
| Dengue | A*24:02 | 4081 | TYGWNIVKL | DENV 3 NS5 2608-2616 |
| Dengue | A*24:02 | 4082 | TYGWNLVRL | DENV 2 NS5 2609-2617 |
| Dengue | A*24:02 | 4083 | TYGWNLVKL | DENV 1, 4 NS5 2611-2619 |
| Dengue | A*24:02 | 4633 | RYLEFEALGF | DENV 3 NS5 2971-2980 |
| Dengue | A*24:02 | 4634 | TYFQRVLIF | DENV 2 M 261-269 |
| Dengue | B*07:02 | 3909 | APTRVVAAEM | Dengue NS3 serotype 2 222-231 |
| Dengue | B*07:02 | SPARLASAI | Genome polyprotein (812-820) | |
| Dengue | B*08:01 | 3915 | RIKQKGIL | Dengue NS3 25-32 |
| Dengue | B*08:01 | 3925 | LEKTKKDL | Dengue NS4a 6-13 |
| Dengue | B*15:01 | 3912 | CLIPTAMAF | Dengue C 107-115 |
| Dengue | B*35:01 | 3908 | TPEGIIPTL | Dengue NS3 500-508 |
| Dengue | B*40:01 | 3924 | GEARKTFVEL | Dengue NS3 528-537 |
| Ebola | A*02:01 | FLYDRLAST | Glycoprotein 2 (GP2) 160-168 | |
| Ebola | A*02:01 | ILFQRTFSI | glycoprotein (GP) 25-33 | |
| Ebola | A*02:01 | FLLQLNETI | Surface Glycoprotein (GP) 252-260 | |
| Ebola | A*02:01 | RLAKLTEAI | Nucleoprotein (NP) 401-409 | |
| Ebola | A*02:01 | IIQAFEAGV | Nucleoprotein (NP) 56-64 | |
| Ebola | A*02:01 | SLTDRELLL | Viral transcription-activation factor VP30 94-102 | |
| Ebola | A*02:01 | GLMHNQDGL | Glycoprotein (GP) 546-554 | |
| Ebola | A*02:01 | SADSFLLML | nucleoprotein NP 69-77 | |
| Ebola | A*02:01 | FLSFASLFL | Nucleoprotein (NP) 149-157 | |
| Ebola | B*08:01 | FRLMRTNFL | nucleoprotein NP (201-209) | |
| Ebola | B*35:01 | FPQLSAIAL | nucleoprotein NP 313-321 | |
| EBV | A*01:01 | FLQRTDLSY | Epstein-Barr nuclear antigen 3A (EBNA3A) 282-290 | |
| EBV | A*02:01 | 1 | GLCTLVAML | EBV BMLF-1 259-267 |
| EBV | A*02:01 | 42 | CLGGLLTMV | EBV LMP-2 426-434 |
| EBV | A*02:01 | 409 | YLLEMLWRL | EBV LMP-1 125-133 |
| EBV | A*02:01 | 410 | YLQQNWWTL | EBV LMP1 159-167 |
| EBV | A*02:01 | 462 | YVLDHLIVV | EBV BRLF1 109-117 |
| EBV | A*02:01 | 666 | FLYALALLL | EBV LMP-2 356-364 |
| EBV | A*02:01 | 872 | TLDYKPLSV | EBV BMRF1 208-216 |
| EBV | A*02:01 | 1616 | LLDFVRFMGV | EBV EBNA-3C 284-293 |
| EBV | A*02:01 | 2292 | FLDKGTYTL | EBV BALF-4 276-284 |
| EBV | A*02:01 | 3462 | FMVFLQTHI | EBV EBNA-1 (562-570) |
| EBV | A*03:01 | 727 | RLRAEAQVK | EBV EBNA 3A 603-611 |
| EBV | A*03:01 | 1838 | RVRAYTYSK | EBV BRLF1 |
| EBV | A*03:01 | QVATEGLAK | Tripartite terminase subunit UL28 homolog (BALF3) 540-548 | |
| EBV | A*11:01 | 199 | IVTDFSVIK | EBV EBNA-4 416-424 |
| EBV | A*11:01 | 508 | SSCSSCPLSK | EBV LMP-2 340-349 |
| EBV | A*11:01 | 4183 | SSCSSCPLTK | EBV LMP-2_EBVG 339-348 |
| EBV | A*11:01 | 639 | ATIGTAMYK | EBV BRLF1 134-142 |
| EBV | A*11:01 | 726 | AVFDRKSDAK | EBNA3B 399-408 |
| EBV | A*24:02 | 420 | TYGPVFMCL | EBV LMP-2 419-427 |
| EBV | A*24:02 | 648 | PYLFWLAAI | EBV LMP2 131-139 |
| EBV | A*24:02 | 683 | TYGPVFMSL | EBV LMP2 419-427 |
| EBV | B*07:02 | 44 | RPPIFIRRL | EBV EBNA-3A 247-255 |
| EBV | B*07:02 | 647 | RPQGGSRPEFVKL | EBV BMRF1 116-128 |
| EBV | B*07:02 | 2305 | QPRAPIRPI | EBV EBNA-3C 881-889 |
| EBV | B*08:01 | 73 | FLRGRAYGL | EBV EBNA-3A 193-201 |
| EBV | B*08:01 | 190 | RAKFKQLL | EBV BZLF-1 190-197 |
| EBV | B*08:01 | 489 | QAKWRLQTL | EBV EBNA3A 158-166 |
| EBV | B*35:01 | 107 | YPLHEQHGM | EBV EBNA-3A 458-466 |
| EBV | B*35:01 | 399 | EPLPQGQLTAY | EBV BZLF-1 54-64 |
| EBV | B*35:01 | 3033 | HPVAEADYFEY | EBV EBNA-1 407-417(4A) |
| EBV | B*35:01 | LPPHDITPY | EBNA-3C protein 98-106 | |
| EBV | B*35:01 | VPGSETMCY | Envelope glycoprotein gp110 544–552 | |
| EBV | B*40:01 | 692 | IEDPPFNSL | EBV LMP2 200-208 |
| HAV | A*02:01 | 2257 | LLYNCCYHV | Hepatitis A Virus polyprotein 2027-2034 |
| HAV | B*07:02 | 2164 | HPRLAQRIL | Hepatitis A Virus polyprotein 1877-1885 |
| HBV | A*01:01 | 3939 | LLDTASALY | Core 30-38 |
| HBV | A*02:01 | 23 | FLPSDFFPSV | HBV core antigen 18-27 |
| HBV | A*02:01 | 27 | FLLTRILTI | HBV envelope 183-191 |
| HBV | A*02:01 | 28 | GLSPTVWLSV | HBV surface antigen 185-194 |
| HBV | A*02:01 | 31 | WLSLLVPFV | HBV surface antigen 172-181 |
| HBV | A*02:01 | 32 | FLLSLGIHL | HBV polymerase 573-581 |
| HBV | A*02:01 | 283 | FLPSDFFPSI | HBV core 18-27 (subtype ADR4) |
| HBV | A*02:01 | 500 | VLHKRTLGL | X 92-100 |
| HBV | A*02:01 | 778 | GLSRYVARL | HBV Pol 455-463 |
| HBV | A*02:01 | 1194 | YMDDVVLGA | Polymerase 548-556 |
| HBV | A*02:01 | 2829 | KLHLYSHPI | Pol 502-510 |
| HBV | A*02:01 | 3934 | ELMTLATWV | core protein 64-72 |
| HBV | A*02:01 | ILLLCLIFL | envelope protein (L-HBsAg) 249-257 | |
| HBV | A*02:01 | GLYSSTVPV | polymerase 61-69 | |
| HBV | A*02:01 | LLVPFVQWFV | Large envelope protein (L-HBsAg) 338-347 | |
| HBV | A*02:01 | SLNFLGGTTV | Large envelope protein / Surface antigen (HBsAg or preS/S region) 201-210 | |
| HBV | A*02:01 | ILSTLPETTV | Capsid protein / Core protein (HBcAg) 139–148 | |
| HBV | A*02:01 | FLGGTPVCL | Large envelope protein (surface antigen / HBsAg) 204-212 | |
| HBV | A*02:01 | FLPSDFFPAV | core antigen protein (HBcAg) 18-27 | |
| HBV | A*02:01 | VLQAGFFLL | Large envelope protein / Hepatitis B surface antigen (HBsAg or Pre-S2/S protein) 177-185 | |
| HBV | A*02:01 | STLPETTVV | Hepatitis B virus capsid / core protein (HBcAg) 141–149 | |
| HBV | A*02:01 | GMLPVCPLI | Large surface antigen / large envelope protein (Pre-S/S protein 276–284 | |
| HBV | A*02:01 | VLEYLVSFGV | Core/Capsid protein (HBcAg / nucleocapsid protein) 115-124 | |
| HBV | A*02:01 | LVLLDYQGML | HBsAg protein 95-104 | |
| HBV | A*02:01 | FLLAQFTSA | polymerase (HBpol / Protein P) 513-521 | |
| HBV | A*02:01 | AMSTTDLEA | Hepatitis B virus X protein (HBx) 102-110 | |
| HBV | A*03:01 | YMDDVVLGAK | DNA polymerase 538-547 | |
| HBV | A*11:01 | 377 | YVNVNMGLK | HBV core antigen 88-96 |
| HBV | A*11:01 | 2659 | YVNTNMGLK | Core 88-96 |
| HBV | A*11:01 | 3941 | STLPETTVVRR | Core 141-151 |
| HBV | A*11:01 | VTKYLPLDK | polymerase 119-127 | |
| HBV | A*11:01 | TVNENRRLK | polymerase protein (Protein P / POL) 100-108 | |
| HBV | A*11:01 | TLWKAGILYK | DNA polymerase 150-159 | |
| HBV | A*11:01 | SVVRRAFPH | Protein P 535-543 | |
| HBV | A*24:02 | 378 | EYLVSFGVW | HBV core 117-125 |
| HBV | A*24:02 | 413 | KYTSFPWLL | HBV polymerase 756-764 |
| HBV | A*24:02 | 3935 | FFPSIRDLL | core protein 23-31 |
| HBV | A*24:02 | KYTAFPWLL | polymerase (756-764) | |
| HBV | A*24:02 | PFLPLLPIF | large envelope protein (surface antigen / HBsAg) 211-219 | |
| HBV | B*07:02 | 701 | LPSDFFPSV | Core 19-27 |
| HBV | B*08:01 | 3937 | GLKILQLL | external core Ag |
| HBV | H-2Kb | 422 | ILSPFLPLL | HBV surface antigen 208-216 |
| HBV | H-2Kb | 477 | VWLSVIWM | HBV Surface antigen 190-197 |
| HBV | H-2Kb | 1431 | MGLKFRQL | HBV core 93-100 |
| HBV | H-2Kb | VSAAFYHL | P protein 425-442 | |
| HBV | H-2Kd | KYLPLDKGI | Protein P 121-129 | |
| HBV | H-2Kd | HYFQTRHYL | polymerase 140-148 | |
| HBV | H-2Kd | 529 | WYWGPSLYSI | large envelope 362-371 |
| HBV | H-2Kd | 526 | SYVNTNMGL | Core 87-95 |
| HBV | H-2Ld | 129 | IPQSLDSWWTSL | HBV surface antigen 28-39 |
| HCV | A*01:01 | 740 | ATDALMTGY | HCV NS3 1435-1443 |
| HCV | A*01:01 | 1066 | ATDALMTGF | HCV NS3 1436-1444 |
| HCV | A*02:01 | 2 | DLMGYIPAV | HCV core 132-140 |
| HCV | A*02:01 | 3 | CINGVCWTV | HCV NS3 1073-1081 |
| HCV | A*02:01 | 4 | YLLPRRGPRL | HCV core 35-44 |
| HCV | A*02:01 | 36 | VLSDFKTWL | HCV NS5a 1987-1995 |
| HCV | A*02:01 | 37 | ALYDVVTKL | HCV NS5b 2594-2602 |
| HCV | A*02:01 | 40 | KLVALGINAV | HCV NS3 1406-1415 |
| HCV | A*02:01 | 243 | KLSGLGLNAV | HCV NS3 1406-1415 |
| HCV | A*02:01 | 172 | LLFNILGGWV | HCV NS4b 1807-1816 |
| HCV | A*02:01 | 242 | KLSGLGINAV | HCV NS3 1406-1415 |
| HCV | A*02:01 | 491 | DLMGYIPLV | HCV core 132-140 |
| HCV | A*02:01 | 858 | CVNGVCWTV | HCV NS3 1073-1081 |
| HCV | A*02:01 | 1094 | GLQDCTMLV | HCV NS5B 2727-2735 |
| HCV | A*02:01 | KLTGLGLNAV | Non-structural protein 3 (NS3) 1406-1415 | |
| HCV | A*02:01 | SLMAFTAAV | Non-structural protein region (NS4B) 1789–1797 | |
| HCV | A*02:01 | KLVAMGINAV | non-structural protein 3 (NS3) 1406-1415 | |
| HCV | A*02:01 | DLMGYIPVV | C7A2 protein fragment | |
| HCV | A*02:01 | RLGPVQNEI | Non-structural protein 3 (NS3) helicase 601-609 | |
| HCV | A*02:01 | CISGVCWTV | non-structural protein 3 (NS3) 1073-1081 | |
| HCV | A*02:01 | NLPGCSFSI | polyprotein 168-176 | |
| HCV | A*02:01 | TIGGVMWTV | protease-helicase 47-55 | |
| HCV | A*02:01 | AVNGVMWTV | Non-structural protein 3 (NS3) 1073-1081 | |
| HCV | A*02:01 | WMNRLIAFA | Genome polyprotein / NS4B protein 204-212 | |
| HCV | A*02:01 | WLGNIIMFA | NS5B RNA-dependent RNA polymerase 2827–2835 | |
| HCV | A*02:01 | WLGNIIMYA | Genome polyprotein / Non-structural protein 5B (NS5B RNA polymerase) 2831-2839 | |
| HCV | A*03:01 | 35 | RVCEKMALY | HCV NS5B 2588-2596 |
| HCV | A*03:01 | VTLTHPITK | Genome polyprotein / Non-structural protein 4A (NS4A) 1635-1643 | |
| HCV | A*03:01 | KTSERSQPR | Genome polyprotein 51–59 | |
| HCV | A*03:01 | QLFTFSPRR | Genome polyprotein 289-297 | |
| HCV | A*24:02 | 415 | AYSQQTRGL | HCV NS3 1031-1039 |
| HCV | B*07:02 | 742 | GPRLGVRAT | HCV core 41-49 |
| HCV | B*07:02 | 845 | DPRRRSRNL | HCV core 111-119 |
| HCV | B*08:01 | 721 | HSKKKCDEL | HCV NS3 1395-1403 |
| HCV | B*27:05 | 871 | ARMILMTHF | NS5B 2841-2849 |
| HCV | B*35:01 | 565 | HPNIEEVAL | HCV NS3 1359-1367 |
| HCV | B*35:01 | 942 | CPNSSIVY | HCV E1 207-214 |
| HCV | B*40:01 | 939 | REISVPAEIL | HCV NS5a 2266-2275 |
| HCV | H-2Db | 791 | GAVQNEVTL | HCV NS3 1629-1637 |
| HDV | A*02:01 | KLEEENPWL | Large delta antigen 43-51 | |
| HDV | A*02:01 | KLEDDNPWL | large delta antigen 43-51 | |
| HDV | B*35:01 | FPWDILFPS | large hepatitis delta antigen (L-HDAg) 194-202 | |
| HDV | B*35:01 | FPWDILFPA | large delta antigen 194-202 | |
| HEV | A*02:01 | GLLDFALEL | open reading frame 2 (ORF2) 166-174 | |
| HEV | A*02:01 | SLFWNEPAI | Open Reading Frame 1 (ORF1) 1122-1130 | |
| HEV | A*02:01 | LLWNTVWNM | ORF1 non-structural polyprotein 1527–1535 | |
| HHV | B*08:01 | MAREKNDL | HHV-6 U53 proteinase 431-438 | |
| HHV | B*08:01 | TNKIKEQL | HHV-6 U31 tegument protein 1135-1142 | |
| HHV | B*08:01 | EFKSKFSTL | HHV-6A Immediate-Early 1 (IE-A / IE1) 1489-1497 | |
| HHV | B*08:01 | FEKERFLFL | HHV-6 capsid assembly and DNA maturation 233-241 | |
| HHV | B*08:01 | NVKHKKNPL | HHV6 DNA-binding protein (DBP) 757-765 | |
| HHV | B*08:01 | DFKSKYLTL | HHV-6B U86 Immediate-early protein 2 (IE2) 314-322 | |
| HHV | B*08:01 | EMRLRMIL | HHV-6B Protein U26 open reading frame (ORF) 92-99 | |
| HHV | B*08:01 | VVKGKVLSI | HHV-6 major DNA binding protein 1008-1016 | |
| HHv | B*08:01 | QTRQKFHL | HHV-6 major DNA binding protein 110-117 | |
| HHV | B*08:01 | EARRRLAEM | HHV-6 U3 257-265 | |
| HHV | B*08:01 | EGRERILTV | HHV-6B DNA replication protein U79/U80 105–113 | |
| HHV | B*08:01 | RSKPRHMCV | HHV-6 U7 protein 345-353 | |
| HIV/SIV | A*01:01 | GTEEIKSLY | gag protein 71-79 | |
| HIV/SIV | A*02:01 | 10 | SLYNTVATL | HIV-1 gag p17 76-84 |
| HIV/SIV | A*02:01 | 84 | ILKEPVHGV | HIV-1 RT 476-484 |
| HIV/SIV | A*02:01 | 174 | TLNAWVKVV | HIV-1 gag p24 19-27 |
| HIV/SIV | A*02:01 | 246 | KLTPLCVTL | HIV-1 env gp120 90-98 |
| HIV/SIV | A*02:01 | 430 | GLADQLIHL | HIV-1 Vif 101-109 |
| HIV/SIV | A*02:01 | 799 | LTFGWCFKL | HIV-1 Nef 137-145 |
| HIV/SIV | A*02:01 | 1147 | FLGKIWPS | Gag 433-440 |
| HIV/SIV | A*02:01 | 1240 | ALVEMGHHA | HIV Vpu 66-74 |
| HIV/SIV | A*02:01 | 1241 | RTLNAWVKV | HIV Gag 150-158 |
| HIV/SIV | A*02:01 | 1244 | NVWATHACV | HIV Env gp 67-7 |
| HIV/SIV | A*02:01 | 1537 | SLLNATAIAV | HIV env 816-825 |
| HIV/SIV | A*02:01 | 3401 | SLFNTVATL | HIV gag 77-85 |
| HIV/SIV | A*02:01 | 3402 | SLVKHHMYI | HIV Vif 23-31 |
| HIV/SIV | A*02:01 | 3403 | VIYHYVDDL | HIV Pol |
| HIV/SIV | A*02:01 | SLYNLVATL | Gag polyprotein (p17) 77-85 | |
| HIV/SIV | A*02:01 | SLYNTIAVL | Gag polyprotein (p17 matrix protein) 77–85 | |
| HIV/SIV | A*02:01 | SLYNTVAFL | Group-specific antigen (Gag) core protein | |
| HIV/SIV | A*02:01 | AIIRILQQL | Viral protein R (Vpr) 59-67 | |
| HIV/SIV | A*02:01 | SVYNTVATL | Gag matrix protein p17 (77–85) | |
| HIV/SIV | A*03:01 | 109 | QVPLRPMTYK | HIV-1 nef 73-82 |
| HIV/SIV | A*03:01 | 194 | RLRPGGKKK | HIV-1 gag p17 19-27 |
| HIV/SIV | A*03:01 | 1496 | AIFQSSMTK | HIV pol 325-333 |
| HIV/SIV | A*03:01 | KIRLRPGGK | Group-specific antigen (Gag) polyprotein p17 matrix protein 18–26 | |
| HIV/SIV | A*03:01 | AIFQCSMTK | Gag-Pol polyprotein 313–321 | |
| HIV/SIV | A*11:01 | 1486 | AVDLSHFLK | HIV nef 84-92 |
| HIV/SIV | A*11:01 | 1686 | ACQGVGGPGHK | HIV gag p24 |
| HIV/SIV | A*24:02 | 411 | RYPLTFGWCY | HIV-1 Nef 134-143 |
| HIV/SIV | A*24:02 | 419 | RYLKDQQLL | HIV-1 gag gp41 67-75 |
| HIV/SIV | A*24:02 | 1805 | RYLRDQQLL | HIV env |
| HIV/SIV | A*24:02 | 3099 | RYPLTFGWCF | HIV NEF 143-152 |
| HIV/SIV | A*24:02 | 3238 | RYPLTFGW | HIV nef |
| HIV/SIV | A*24:02 | KYQLKHIVW | gag polyprotein 28-36 | |
| HIV/SIV | A*29:02 | 3392 | LYNTVATLY | HIV gag 79-86 |
| HIV/SIV | A*29:02 | 3395 | SFDPIPIHY | HIV env 216-224 |
| HIV/SIV | A*29:02 | 3396 | SFNCRGEFFY | HIV env 382-391 |
| HIV/SIV | B*07:02 | 196 | IPRRIRQGL | HIV-1 env gp120 848-856 |
| HIV/SIV | B*07:02 | 257 | TPGPGVRYPL | HIV-1 nef 128-137 |
| HIV/SIV | B*07:02 | 877 | GPGHKARVL | HIV gag p24 223-231 |
| HIV/SIV | B*08:01 | 193 | FLKEKGGL | HIV-1 nef 90-97 |
| HIV/SIV | B*08:01 | 195 | GEIYKRWII | HIV-1 gag p24 261-269 |
| HIV/SIV | B*08:01 | 879 | EIYKRWII | HIV p24 gag 128-135 |
| HIV/SIV | B*08:01 | 1536 | YLKDQQLL | Env 586-593 |
| HIV/SIV | B*15:01 | 1072 | RLRPGGKKKY | HIV-1 p17 20-29 |
| HIV/SIV | B*27:05 | 294 | KRWIILGLNK | HIV-1 gag p24 265-274 |
| HIV/SIV | B*27:05 | 874 | KRWIIMGLNK | HIV-1 Gag p24 263-272 |
| HIV/SIV | B*27:05 | 2306 | GRAFVTIGK | HIV-1 gp100 103-111 |
| HIV/SIV | B*35:01 | 255 | NPDIVIYQY | HIV-1 HIV-1 RT 328-336 |
| HIV/SIV | B*35:01 | 1211 | VPLDEDFRKY | HIV-1 HIV-1 RT 273-282 |
| HIV/SIV | B*40:01 | 840 | KEKGGLEGL | HIV-1 Nef 92-100 |
| HIV/SIV | H-2Db | 719 | AAVKNWMTQTL | SIV gag |
| HIV/SIV | H-2Dd | IGPGRAFYT | Envelope glycoprotein gp160 precursor 314-322 | |
| HIV/SIV | H-2Dd | IGPGRAFYTT | Envelope glycoprotein gp160 306-315 | |
| HIV/SIV | H-2Dd | IGPGRAFYVV | IV-1 envelope glycoprotein gp120 (V3 loop region) | |
| HIV/SIV | H-2Dd | 177 | RGPGRAFVTI | HIV-1 IIIB gp120 318-327 |
| HIV/SIV | H-2Dd | 1684 | IGPGRAFYA | HIV-1 US4 gp120 318-326 |
| HIV/SIV | H-2Kd | 176 | AMQMLKETI | HIV-1 gag p24 199-207 |
| HIV/SIV | H-2Kd | 403 | AMQMLKDTI | HIV gag p24 197-205 |
| HIV/SIV | Mamu-A*01 | 1110 | CTPYDINQM | SIV Gag 181-189 |
| HIV/SIV | Mamu-A*02 | 1111 | YTSGPGIRY | SIV Nef 159-167 |
| HIV/SIV | Mamu-A*02 | 1112 | GSENLKSLY | SIV Gag 71-79 |
| HMPV | A*02:01 | YMVQLPIFGV | Fusion glycoprotein F0 269-278 | |
| HPV | A*01:01 | QVDYYGLYY | Regulatory protein E2 151-159 | |
| HPV | A*01:01 | ISEYRHYCY | Protein E6 80-88 | |
| HPV | A*02:01 | 95 | YMLDLQPETT | HPV 16 E7 11-20 |
| HPV | A*02:01 | 658 | KLPQLCTEL | HPV 16 E6 18-26 |
| HPV | A*02:01 | 2103 | YMLDLQPET | HPV E7 11-19 |
| HPV | A*02:01 | 2312 | MLDLQPETT | HPV 16 E7 12-20 |
| HPV | A*02:01 | SLQDIEITCV | E6 oncoprotein 24-33 | |
| HPV | A*02:01 | KLPDLCTEL | E6 early oncoprotein 13-21 | |
| HPV | A*02:01 | TLQDVSLEVYL | E2 regulatory protein 93-103 | |
| HPV | A*02:01 | YMLDLQAET | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | VLLLWITAA | E5 minor oncoprotein 46-54 | |
| HPV | A*02:01 | YMLDLAPET | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | AMLDLQPET | oncoprotein E7 11-19 | |
| HPV | A*02:01 | YMLDLQPEA | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | YMADLQPET | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | YMLALQPET | E7 oncoprotein 11–19 | |
| HPV | A*02:01 | FAFKDLFVV | E6 oncoprotein of Alphapapillomavirus 7 47-55 | |
| HPV | A*02:01 | YMLDLQPAT | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | YMLDAQPET | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | YALDLQPET | E7 oncoprotein 11-19 | |
| HPV | A*02:01 | ICWGNQLFV | Major capsid protein L1 (HPV16 L1) 349-357 | |
| HPV | A*03:01 | 2064 | KLCLRFLSK | HPV 33 E6 64-72 |
| HPV | A*11:01 | 2067 | NTLEQTVKK | HPV 33E6 86-94 |
| HPV | A*11:01 | SVYGDTLEK | E6 Oncoprotein 84–92 | |
| HPV | A*11:01 | GTTLEQQYNK | E6 oncoprotein 92-101 | |
| HPV | A*11:01 | TTLEQQYNK | E6 oncoprotein 93–101 | |
| HPV | A*24:02 | 3240 | VYDFAFRDL | HPV16 E6 |
| HPV | B*07:02 | 2065 | KPTLKEYVL | HPV 33 E7 5-13 |
| HPV | B*07:02 | WPTTPPRPI | E4 protein 23-31 | |
| HPV | B*35:01 | FAFRDLCIVY | Protein E6 52-61 | |
| HPV | H-2Db | 502H | RAHYNIVTF | HPV 16 E7 49-57 |
| HPV | H-2Db | 3404 | AGVDNRECI | HPV L1 165-173 |
| HPV | H-2Kb | 2560 | EVYDFAFRDL | HPV E6 48-57 |
| HPV | H-2Kb | CLKFYSKI | E6 oncoprotein 73-80 | |
| HSV | A*01:01 | ATDSLNNEY | tegument protein VP11/12 354-362 | |
| HSV | A*01:01 | FTDALGIDEY | Tegument protein VP16 479-488 | |
| HSV | A*01:01 | SALPTNADLY | Tegument protein VP16 90-99 | |
| HSV | A*02:01 | 1152 | VLMIKALEL | Non muscle Myosin-9 741-749 |
| HSV | A*02:01 | 1153 | QLFNHTMFI | Non-muscle Myosin 478-486 |
| HSV | A*02:01 | 3406 | QMARLAWEA | 1116-1124 |
| HSV | A*02:01 | TLLELVVSV | Serine/threonine-protein kinase UL13 389-397 | |
| HSV | A*02:01 | RILGVLVHL | ribonucleoside-diphosphate reductase large subunit (ICP6/ICP10) 425-433 | |
| HSV | A*02:01 | ILIEGIFFA | ribonucleotide reductase subunit 2 184-192 | |
| HSV | A*02:01 | FLWEDQTLL | UL25 major capsid/tegument protein 367–375 | |
| HSV | A*02:01 | SVYPYDEFV | Envelope glycoprotein B (gB) 280-288 | |
| HSV | A*24:02 | AYLPRPVEF | UL37 tegument protein 640–648 | |
| HSV | H-2Db | 3405A | AGPHNDMEI | HSV p56 487-495 |
| HSV | H-2Dd | 3405B | AGPHNDMEI | HSV p56 487-495 |
| HSV | H-2Kb | 188 | SSIEFARL | HSV-1 gp B 498-505 |
| HSV | H-2Kb | QTFDFGRL | ribonucleotide reductase 1 (RR1) 822-829 | |
| HSV | H-2Kd | 3407 | TYWPVVSDI | 207-215 |
| HTLV | A*02:01 | 200 | LLFGYPVYV | Human T-cell lymphotropic virus-1 (HTLV-1) tax 11-19 |
| HTLV | A*02:01 | 2309 | AVLDGLLSL | HTLV bZIP factor 42-50 |
| HTLV | A*02:01 | 3408 | GLLSLEEEL | bZIP factor 26-34 |
| HTLV | A*24:02 | 1043 | SFHSLHLLF | HTLV Tax 301-309 |
| HTLV | A*24:02 | FFQFCPLIF | Envelope glycoprotein (Env) 11–19 | |
| HTLV | B*07:02 | 3400 | LPVSCPEDL | bZIP factor 10-18 |
| Human Parvovirus | A*02:01 | GLCPHCINV | B19 Non-capsid non-structural protein NS-1 613-621 | |
| Human Parvovirus | A*24:02 | FYTPLADQF | B19 Non-capsid protein NS-1 572-580 | |
| Influenza | A*01:01 | 76 | CTELKLSDY | Influenza A (PR8) NP 44-52 |
| Influenza | A*01:01 | 540 | VSDGGPNLY | Influenza A PB1 591-599 |
| Influenza | A*02:01 | 7 | GILGFVFTL | Influenza A MP 58-66 |
| Influenza | A*02:01 | 2295 | ILGFVFTLTV | Influenza A MP 59-68 |
| Influenza | A*02:01 | 3409 | KLGEFYNQMM | Flu BNP 85-94 (Influenza B) |
| Influenza | A*03:01 | 77 | ILRGSVAHK | Influenza A (PR8) NP 265-274 |
| Influenza | A*11:01 | 1513 | SIIPSGPLK | Influenza A MP 13-21 |
| Influenza | A*11:01 | 1720 | RMVLASTTAK | Influenza A MP1 178-187 |
| Influenza | A*11:01 | 1722 | KSMREEYRK | Influenza A MP2 70-78 |
| Influenza | A*24:02 | TYQWIIRNW | RNA polymerase basic protein 2 (PB2) 549-557 | |
| Influenza | B*07:02 | 1743 | QPEWFRNVL | Influenza A PB1 329-337 |
| Influenza | B*07:02 | 1744 | SPIVPSFDM | Influenza A NP 473-481 |
| Influenza | B*08:01 | ELRSRYWAI | Influenza A Nucleoprotein 380-388 | |
| Influenza | B*27:05 | 463 | SRYWAIRTR | Influenza A NP 383-391 |
| Influenza | B*27:05 | RSGAAGAAVK | Influenza A Nucleoprotein 175-184 | |
| Influenza | H-2Db | 9 | ASNENMDAM | Influenza A (NT60) NP 366-374 |
| Influenza | H-2Db | 119 | ASNENMETM | Influenza A (PR8) NP 366-374 |
| Influenza | H-2Db | 3410 | SCLENFRAYV | Influenza A polymerease PA 224-233 |
| Influenza | H-2Db | 120 | SSLENFRAYV | Influenza A (PR8) Polymerase acidic protein 224-233 |
| Influenza | H-2Db | ASNENVETM | Influenza A NP366-374 | |
| Influenza | H-2Kb | IGRFYIQM | Influenza A Nucleoprotein 36-43 | |
| Influenza | H-2Kd | 98 | TYQRTRALV | Influenza A (PR8) NP 147-155 |
| Influenza | H-2Kd | 240 | IYSTVASSL | Influenza A HA 533-541 |
| JC Virus | A*02:01 | 610 | SITEVECFL | VP1 36-44 |
| JC Virus | A*02:01 | 611 | ILMWEAVTL | VP1 100-108 |
| LASV | A*02:01 | LLGTFTWTL | Glycoprotein precursor (GPC / Glycoprotein GP) 258-266 | |
| LCMV | A*02:01 | 2308 | ALPHIIDEV | LCMV envelope gp 10-18 |
| LCMV | A*02:01 | 2310 | YLVSIFLHL | LCMV envelope gp 447-455 |
| LCMV | A*02:01 | 3411 | SLNQTVHSL | NP 69-77 |
| LCMV | H-2Db | 69 | KAVYNFATC | LCMV GP1 33-41 |
| LCMV | H-2Db | 70 | FQPQNGQFI | LCMV NP 396-404 |
| LCMV | H-2Db | 142 | KAVYNFATM | gp33 (C9M) |
| LCMV | H-2Db | 186 | SGVENPGGYCL | LCMV GP 276-286 |
| LCMV | H-2Db | CSANNSHHYI | Pre-glycoprotein polyprotein GP complex 92-101 | |
| LCMV | H-2Kb | 2076 | ISHNFCNL | LCMV GP 118-125 |
| LCMV | H-2Kb | AVYNFATC | glycoprotein precursor (GPC) 34-41 | |
| Listeria | H-2Kd | 178 | GYKDGNEYI | Listeria monocytogenes Listeriolysin 91-99 |
| Malaria | A*02:01 | 314 | YLNKIQNSL | Plasmodium falciparum CSP 334-342 |
| Malaria | H-2Db | 2697 | SQLLNAKYL | Plasmodium berghei ANKA acid phosphatase 40-48 |
| Malaria | H-2Db | SALLNVDNL | Plasmodium berghei thrombospondin-related adhesion protein (TRAP) 130-138 | |
| Malaria | H-2Kd | 376 | SYIPSAEKI | Plasmodium berghei CSP 252-260 |
| Malaria | H-2Kd | 2290 | SYVPSAEQI | Plasmodium CSP |
| Malaria | H-2Kd | 771 | YYIPHQSSL | Plasmodium falciparum Liver stage antigen 1671-1679 |
| MCMV | H-2Dd | SGPSRGRII | Hypothetical protein MuHV1gpm18 346-354 | |
| MCMV | H-2Kb | STYTFVRT | M38 protein 38-45 | |
| MCMV | H-2Kb | SCLEFWQR | M57 protein (816-824) | |
| Measles | A*02:01 | ILPGQDLQYV | Hemagglutinin (H) glycoprotein 516-525 | |
| Measles | A*02:01 | FMYMSLLGV | Matrix (M) protein 50-58 | |
| Measles | A*02:01 | SMYRVFEVGV | Hemagglutinin (H) glycoprotein 250–259 | |
| Measles | A*02:01 | KLWESPQEI | Nonstructural C protein 84-92 | |
| Measles | A*02:01 | LMIDRPYVL | Hemagglutinin (H) protein 30-38 | |
| MERS coronavirus | H-2Kd | KYYSIIPHSI | spike glycoprotein 292-300 | |
| MiHAg | B*08:01 | ELQEKFLSL | Centromere Protein F (CENPF) mitosin 1406-1414 | |
| Minor Histocompatibility Antigen | A*01:01 | 652 | IVDCLTEMY | DRRFY 1521-1529 |
| Minor Histocompatibility Antigen | A*02:01 | 175 | FIDSYICQV | miHAg H-Y (human SMCY) 311-319 |
| Minor Histocompatibility Antigen | A*02:01 | 395 | YIGEVLVSV | HA-2 |
| Minor Histocompatibility Antigen | A*02:01 | 473 | VLHDDLLEA | Minor Histocompatibility Antigen HA-1 137-145 |
| Minor Histocompatibility Antigen | A*02:01 | 581 | RTLDKVLEV | miHAg HA-8 |
| Minor Histocompatibility Antigen | B*07:02 | 1113 | SPSVDKARAEL | MiHAg SMCY 1041-1051 |
| Minor Histocompatibility Antigen | H-2Db | 327 | WMHHNMDLI | miHAg UTY 246-254 |
| Minor Histocompatibility Antigen | H-2Db | 328 | KCSRNRQYL | miHAg SMCY 738-746 |
| Minor Histocompatibility Antigen | H-2Kk | 269 | TENSGKDI | SMCY 1332-1339 |
| Model Antigen | H-2Db | SSLQDGCFI | Red fluorescent protein (drFP583) 111-119 | |
| Model Antigen | H-2Kb | SIITFEKL | OVA | |
| Model Antigen | H-2Kb | IIITFNDL | Peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase 644-651 | |
| Model Antigen | H-2Kb | VQYAFGLP | thyroglobulin precursor 2627-2635 | |
| Model Antigen | H-2Kb | TNQDFIQR | Nischarin 600-608 | |
| Model Antigen | H-2Kd | SYLPTAERL | Synaptotagmin-12 292-300 | |
| Model Antigen | H-2Kd | SYYDVKGDL | Guanylyl cyclase C (GC-C) | |
| Model Antigens | H-2Kb | 93 | SIINFEKL | Ovalbumin 257-264 |
| Model Antigens | H-2Kb | 562 | LTFNYRNL | Histocompatibility antigen 60 39-46 |
| Model Antigens | H-2Kb | 908 | KVVRFDKL | Ovalbumin (subdominant) 55-62 |
| Model Antigens | H-2Kb | 1803 | SIYRYYGL | 2C TCR |
| Model Antigens | H-2Kd | 198 | HYLSTQSAL | Enhanced Green Fluorescent Protein (eGFP) 200-208 |
| Model Antigens | H-2Ld | 74 | TPHPARIGL | E. coli beta-galactosidase 876-884 |
| Mousepox | H-2Dd | VGPSNSPIF | dsRNA binding protein 140-148 | |
| Mpox | H-2Dd | VGPSNSPTF | RNA-binding protein OPG065 140-148 | |
| MuLV | H-2Kb | 828 | KSPWFTTL | MuLV env 622-629 (MC38) |
| MuLV | H-2Ld | 398 | SPSYVYHQF | MuLV env gp70 423-431 |
| Mumps | A*01:01 | YSDPNNHEVY | large protein [Mumps virus genotype G] 1983-1992 | |
| Mumps | A*02:01 | VMNQVIHGV | Hemagglutinin-neuraminidase (HN) glycoprotein 88-96 | |
| Mumps | A*02:01 | LLDSSTTRV | hemagglutinin-neuraminidase (HN) protein 505-513 | |
| Mumps | A*02:01 | ALDQTDIRV | Matrix (M) protein 108–116 | |
| Mumps | A*02:01 | KLIAGVNYI | Matrix (M) protein 161-169 | |
| Mumps | B*07:02 | KPRTSTPVTEF | phosphoprotein 142-152 | |
| Mumps | B*07:02 | APIQGTNLL | phosphoprotein 27-35 | |
| NEGATIVE | A*01:01 | STEGGGLAY | Negative Control | |
| Negative | A*02:01 | N01 | NEGATIVE | Negative Control |
| NEGATIVE | B*07:02 | GPAESAAGL | Negative Control | |
| NEGATIVE | H-2Kd | SYSSAGASI | Negative Control | |
| NEGATIVE | H-2Kd | AYAGSAGSI | Negative Control | |
| Norovirus | A*02:01 | 3214 | TMFPHIIVDV | Norovirus VP1 139-148 |
| Other | A*02:01 | 133 | LLDVPTAAV | Interferon gamma inducible protein (GILT) 30 27-35 |
| Other | A*02:01 | 353 | RILGAVAKV | Vinculin 822-830 |
| Other | A*02:01 | 366 | LMWYELSKI | KSHVF-8 gB.492-500 |
| Other | A*02:01 | 3041 | ILEDIVLTL | Streptococcus pyogenes Cas9 615-623 |
| Other | A*02:01 | 370 | TIHDIILECV | Alpha papillomavirus 9 E6 Protein (22-31) |
| Other | A*02:01 | NLVPMIIHL | Importin subunit alpha-3 protein (KPNA2-related) 368-376 | |
| Other | A*24:02 | KYMTAVVKLF | Human Cytochrome b-245 light chain (CYBA / p22-phox) 71-80 | |
| Other | B*07:02 | TPRNTYKMTSL | Proliferation marker protein Ki-67 844-854 | |
| Other | B*07:02 | SPREFRERAL | WASP homolog associated with actin, membranes and microtubules (WHAMM) 181-190 | |
| Other | B*07:02 | NPATPTSKL | UPF0711 protein C18orf21 127-135 | |
| Other | B*07:02 | LPRVCGTTL | Tumor Necrosis Factor-beta (TNF-beta) 9-17 | |
| Other | B*07:02 | RPLTDNHRSL | DNA damage-inducible protein 1 homolog 2 (DDI2) 52-61 | |
| Other | B*07:02 | SPDSSTPKL | G2 and S phase-expressed protein 1 (GTSE1) 461-469 | |
| Other | B*07:02 | APRAVFPSI | Actin, alpha cardiac muscle 1 28-36 | |
| Other | B*07:02 | APPAEKAPV | Histone H1.2 (12-20) | |
| Other | B*07:02 | APRESAQAI | Proliferation marker protein Ki-67 2789-2797 | |
| Other | B*07:02 | LPRACWREA | Rho GDP-dissociation inhibitor 2 (ARHGDIB) | |
| Other | B*07:02 | APRRPPPPP | Ras and Rab interactor 3 276-284 | |
| Other | B*07:02 | RPWSGPSSV | Helicase with zinc finger domain 2 (HELZ2) | |
| Other | B*07:02 | TARPQSSAL | Homologous recombination OB-fold protein 126-134 | |
| Other | B*08:01 | TAKQKLDPA | Proliferation marker protein Ki-67 1437-1445 | |
| Other | B*35:01 | TPVDDRISL | ATP-dependent RNA helicase DDX20 DEAD-box helicase 20 or DP103 688-696 | |
| Other | E*01:01 | 712 | VMAPRTLIL | C leader sequence peptide |
| Other | E*01:01 | 2355 | VMAPRTLVL | A leader sequence peptide |
| Other | H-2Dk | 339 | RRLGRTLLL | Polyoma virus middle T protein 389-397 |
| Other | H-2Kb | 2331 | TSINFVKI | MHV 524-431 |
| Other | H-2Kd | 62 | RYLKNGKETL | Cw3 170-179 |
| Other | H-2Kd | 458 | KYNKANVFL | NRP-V7 superagonist peptide 8.3 Tg NOD mouse |
| Other | H-2Kd | 3414 | IYNVGQVSI | Leptospira |
| Other | H-2Ld | 3051 | LPNWGKYVL | Rabies Glycoprotein (453-461) |
| Other | Mamu-A*01 | LTPRPIIHAV | ACET(L1) ORF 1 845-854 | |
| Pichende virus | H-2Kb | YTVKFPNM | Nucleoprotein 205-212 | |
| RSV | A*02:01 | 801 | KMLKEMGEV | RSV NP 137-145 |
| RSV | A*02:01 | FLVNYEMKL | Non-structural protein 2 (NS2) 61-69 | |
| RSV | H-2Kd | 149 | KYKNAVTEL | RSV A strain F protein 85-93 |
| RSV | H-2Kd | 154 | SYIGSINNI | Respiratory Syncytial Virus (RSV) M2 82-90 |
| SARS-CoV-1 | A*02:01 | LLLNCLWSV | Spike glycoprotein precursor (HCoV-299E) 77-85 | |
| Sendai Virus | H-2Kb | 56 | FAPGNYPAL | Sendai virus NP 324-332 |
| SeV | H-2Kb | ARGNYPAL | Nucleoprotein 324–332 | |
| SV40 | H-2Kb | 488 | VVYDFLKL | SV40 T antigen 404-411 |
| TBEV | A*02:01 | ILLDNITTL | Non-structural protein 3 (NS3) 1984-1992 | |
| Tick-Borne Encephalitis | B*07:02 | LPLGHRLWL | non-structural protein NS4B 2496-2504 | |
| Toxoplasma gondii | H-2Kb | 2156 | SVLAFRRL | tgd057 57-64 |
| Toxoplasma gondii | B*07:02 | LPQFATAAT | dense granule protein 7 (GRA7) 20-28 | |
| Toxoplasma gondii | H-2Ld | IPAAAGRFF | Rhoptry protein 7 (ROP7) 161-169 | |
| Toxoplasma gondii | H-2Ld | SPMNGGYYM | Dense granule protein 4 (GRA4) 107-115 | |
| Trypanosoma Cruzi | H-2Kb | 708 | ANYNFTLV | Trypanosoma cruzi SP 536-543 |
| Trypanosoma Cruzi | H-2Kb | 964 | VNHRFTLV | Trypanosoma cruzi ASP-2 553-560 |
| Trypanosoma cruzi | H-2Kk | 3415 | TEWETGQI | ASP-2 320-327 |
| Tuberculosis | A*01:01 | QSSFYSDWY | Antigen 85-B precursor (85B) 115-123 | |
| Tuberculosis | A*02:01 | 276 | KLIANNTRV | Mycobacterium bovis antigen 85-A 200-208 |
| Tuberculosis | A*02:01 | 324 | GLPVEYLQV | Mycobacterium bovis antigen 85-A 6-14 |
| Tuberculosis | A*02:01 | 619 | GILTVSVAV | 16 kDa |
| Tuberculosis | A*02:01 | 620 | AMASTEGNV | ESAT-6 |
| Tuberculosis | A*02:01 | 2221 | VLTDGNPPEV | 19 kDa |
| Tuberculosis | A*02:01 | KLQERLAKL | Heat shock protein 65 (Hsp65, also known as 65 kDa chaperonin or GroEL homolog) 362-370 | |
| Tuberculosis | A*02:01 | FLLGLLFFV | Rv1490 hypothetical protein 325–333 | |
| Tuberculosis | A*02:01 | LMIGTAAAV | Antigen 85B (Ag85B) 15-23 | |
| Tuberculosis | A*02:01 | FIYAGSLSAL | Antigen 85-B precursor (Ag85B or Rv1886c) 143-152 | |
| Tuberculosis | A*02:01 | GMGPSLIGL | Antigen 85A (Ag85A) 198-206 | |
| Tuberculosis | A*02:01 | NLARTISEA | 6 kDa early secretory antigenic target (ESAT-6) | |
| Tuberculosis | A*02:01 | KLVANNTRL | Secretory protein Antigen 85B (Ag85B) 199-207 | |
| Tuberculosis | A*02:01 | GINTIPIAL | PPE family proteins 126-134 | |
| Tuberculosis | A*02:01 | MMARDTAEA | TB10.4 / EsxH (an ESAT-6-like secreted antigenic protein) 83-91 | |
| Tuberculosis | A*02:01 | FIYAGSLSA | antigen 85B (Ag85B) 183-191 | |
| Tuberculosis | A*11:01 | AVMAGIVRAAK | diacylglycerol O-acyltransferase, partial 194-204 | |
| Tuberculosis | A*24:02 | KYIFPGGLL | Cyclopropane fatty acid synthase (Rv0447c) 386-394 | |
| Tuberculosis | A*24:02 | WYYQSGLSI | Antigen 85-B (Ag85B) 100-108 | |
| Tuberculosis | A*24:02 | IYAGSLSAL | Secreted antigen Ag85B (184-192) | |
| Tuberculosis | B*07:02 | GPSLIGLAM | Antigen 85 complex 200-208 | |
| Tuberculosis | H-2Db | 547 | AIQGNVTSI | Mycobacterium tuberculosis ESAT-6 17-25 |
| Tuberculosis | H-2Kb | 764 | IMYNYPAM | Mycobacterium tuberculosis TB10.4 4-11 |
| Tuberculosis | H-2Kb | 769 | IMYNYPAML | Mycobacterium tuberculosis TB10.4 4-12 |
| Tuberculosis | H-2Kd | 1263 | VYAGAMSGL | Mtb85A 145-152 |
| Tuberculosis | H-2Ld | 158 | MPVGGQSSF | Mycobacterium tuberculosis Ag85A 70-78 |
| Vaccinia | A*02:01 | 703 | KVDDTFYYV | Vaccinia virus Host range protein 2 74-82 |
| Vaccinia | A*02:01 | 978 | ILDDNLYKV | Vaccinia virus Copenhagen Protein G5 18-26 |
| Vaccinia | A*02:01 | VLYDEFVTI | A6L virion core/structural protein 6-14 | |
| Vaccinia | H-2Kb | 733 | TSYKFESV | Vaccinia virus WR epitope B8R 20-27 |
| Vaccinia | H-2Kb | VIYIFTVRL | Protein L2 53-61 | |
| Varicella Zoster Virus | A*02:01 | 995 | ALWALPHAA | IE62 593-601 |
| Varicella Zoster Virus | A*02:01 | ILIEGIFFV | Ribonucleoside-diphosphate reductase small subunit 2 (RNR2) 156-164 | |
| Varicella Zoster Virus | H-2Db | RALINLIYC | Immediate-early protein 62 (IE62) 527-535 | |
| Vesicular Stomatitis Virus | H-2Kb | 373 | RGYVYQGL | VSV NP 52 |
| Vesicular Stomatitis Virus | H-2Ld | 622 | MPYLIDFGL | VSV N 275-283 |
| VSBV | A*02:01 | FLCLLIPGL | Nucleoprotein (N antigen) 82-90 | |
| VSV | H-2Db | FSLLNIYRI | RNA-directed RNA polymerase L 262-270 | |
| VSV | H-2Kb | NSYLYGAL | Nucleoprotein 69-77 | |
| VSV | H-2Kb | LGLRYKKL | Phosphoprotein 248-255 | |
| West Nile | A*02:01 | 1320 | RLDDDGNFQL | West Nile Virus NY-99 polyprotein precursor (1452-1461) |
| West Nile | A*02:01 | 1322 | ATWAENIQV | West Nile virus NY-99 polyprotein precursor 3390-3398 |
| West Nile | A*02:01 | 1327 | YTMDGEYRL | West Nile virus NY-99 polyprotein precursor 2023-2031 |
| West Nile | H-2Db | 663 | LGMSNRDFL | West Nile Virus polyprotein 294-302 |
| West Nile Virus | A*02:01 | 1321 | SVGGVFTSV | WNV envelope gp 430-438 |
| West Nile Virus | A*02:01 | 1324 | SLFGQRIEV | WNV nonstructural protein 4B 15-23 |
| Yellow Fever | A*02:01 | VLAGWLFHV | Non-structural protein 2B (NS2B) 1471-1479 | |
| Yellow Fever | A*02:01 | LLWNGPIAV | non-structural protein 4B (NS4B) | |
| Yellow Fever Virus | A*02:01 | 2097 | LLWNGPMAV | NS4B 214-222 |
| Yellow Fever virus | C*06:02 | 3942 | TRRFLPQIL | NS3 205-213 |
| Yellow Fever Virus | H-2Kb | 1182 | ATLTYRML | Yellow Fever Virus 17D polyprotein 268-275 |
| Zika | H-2Db | IGVSNRDFV | polyprotein 294-302 |
